<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A8FD2E78-8E69-4795-ACD1-F16537632D06"><gtr:id>A8FD2E78-8E69-4795-ACD1-F16537632D06</gtr:id><gtr:name>International Partnership for Microbicides (IPM)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/75C924D5-5134-4F72-AFFE-AD1655EE48F8"><gtr:id>75C924D5-5134-4F72-AFFE-AD1655EE48F8</gtr:id><gtr:name>FHI 360</gtr:name><gtr:address><gtr:line1>359 Blackwell Street</gtr:line1><gtr:line2>Suite 200</gtr:line2><gtr:postCode>27701</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DE956CB8-1DF4-49EB-BC34-78BD6095649A"><gtr:id>DE956CB8-1DF4-49EB-BC34-78BD6095649A</gtr:id><gtr:name>University of KwaZulu-Natal</gtr:name><gtr:address><gtr:line1>Govan Mbeki Centre</gtr:line1><gtr:line2>Westville Campus</gtr:line2><gtr:line3>Private Bag X54001</gtr:line3><gtr:postCode>4000</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/09E4EB72-51A4-42FB-BB8C-F82B831F42F7"><gtr:id>09E4EB72-51A4-42FB-BB8C-F82B831F42F7</gtr:id><gtr:name>Indevus Pharmaceuticals, Inc.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C2D3630B-98B3-4FCD-9508-3EDCB6C3EA72"><gtr:id>C2D3630B-98B3-4FCD-9508-3EDCB6C3EA72</gtr:id><gtr:name>Manhi?a Health Research Centre (CISM)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FDEC91A0-8557-4ECC-9E72-E3402494D6DB"><gtr:id>FDEC91A0-8557-4ECC-9E72-E3402494D6DB</gtr:id><gtr:name>University of Zambia</gtr:name><gtr:address><gtr:line1>Box 50110</gtr:line1><gtr:line2>Nationalis Road</gtr:line2><gtr:postCode>10101</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Zambia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A2EC0DF1-142D-422A-AB83-724ABEC8BE19"><gtr:id>A2EC0DF1-142D-422A-AB83-724ABEC8BE19</gtr:id><gtr:name>University of the Witwatersrand</gtr:name><gtr:address><gtr:line1>University of the Witwatersrand</gtr:line1><gtr:line2>WITS</gtr:line2><gtr:line3>2050</gtr:line3><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/ACCAA472-353D-4CD6-814A-04677AE5E921"><gtr:id>ACCAA472-353D-4CD6-814A-04677AE5E921</gtr:id><gtr:name>MRC/UVRI Uganda Research Unit on AIDS</gtr:name><gtr:address><gtr:line1>Uganda Virus Research Institute</gtr:line1><gtr:line2>51-59 Nakiwogo Road, PO box 49</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Uganda</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/421AD70F-9A6E-48CE-9C42-6C508F1FBAD8"><gtr:id>421AD70F-9A6E-48CE-9C42-6C508F1FBAD8</gtr:id><gtr:name>Eastern Virginia Medical School (EVMS)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1EC5A569-85E9-44B3-AD1F-049F1003C9C6"><gtr:id>1EC5A569-85E9-44B3-AD1F-049F1003C9C6</gtr:id><gtr:name>University of Barcelona</gtr:name><gtr:address><gtr:line1>Universidad de Barcelona</gtr:line1><gtr:line2>Av Diagonal 647</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Spain</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A33EFB82-6D09-41B1-880E-842746F6062E"><gtr:id>A33EFB82-6D09-41B1-880E-842746F6062E</gtr:id><gtr:name>Medical Research Council of South Africa (MRC)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A8FD2E78-8E69-4795-ACD1-F16537632D06"><gtr:id>A8FD2E78-8E69-4795-ACD1-F16537632D06</gtr:id><gtr:name>International Partnership for Microbicides (IPM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/75C924D5-5134-4F72-AFFE-AD1655EE48F8"><gtr:id>75C924D5-5134-4F72-AFFE-AD1655EE48F8</gtr:id><gtr:name>FHI 360</gtr:name><gtr:address><gtr:line1>359 Blackwell Street</gtr:line1><gtr:line2>Suite 200</gtr:line2><gtr:postCode>27701</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DE956CB8-1DF4-49EB-BC34-78BD6095649A"><gtr:id>DE956CB8-1DF4-49EB-BC34-78BD6095649A</gtr:id><gtr:name>University of KwaZulu-Natal</gtr:name><gtr:address><gtr:line1>Govan Mbeki Centre</gtr:line1><gtr:line2>Westville Campus</gtr:line2><gtr:line3>Private Bag X54001</gtr:line3><gtr:postCode>4000</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/09E4EB72-51A4-42FB-BB8C-F82B831F42F7"><gtr:id>09E4EB72-51A4-42FB-BB8C-F82B831F42F7</gtr:id><gtr:name>Indevus Pharmaceuticals, Inc.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C2D3630B-98B3-4FCD-9508-3EDCB6C3EA72"><gtr:id>C2D3630B-98B3-4FCD-9508-3EDCB6C3EA72</gtr:id><gtr:name>Manhi?a Health Research Centre (CISM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FDEC91A0-8557-4ECC-9E72-E3402494D6DB"><gtr:id>FDEC91A0-8557-4ECC-9E72-E3402494D6DB</gtr:id><gtr:name>University of Zambia</gtr:name><gtr:address><gtr:line1>Box 50110</gtr:line1><gtr:line2>Nationalis Road</gtr:line2><gtr:postCode>10101</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Zambia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A2EC0DF1-142D-422A-AB83-724ABEC8BE19"><gtr:id>A2EC0DF1-142D-422A-AB83-724ABEC8BE19</gtr:id><gtr:name>University of the Witwatersrand</gtr:name><gtr:address><gtr:line1>University of the Witwatersrand</gtr:line1><gtr:line2>WITS</gtr:line2><gtr:line3>2050</gtr:line3><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ACCAA472-353D-4CD6-814A-04677AE5E921"><gtr:id>ACCAA472-353D-4CD6-814A-04677AE5E921</gtr:id><gtr:name>MRC/UVRI Uganda Research Unit on AIDS</gtr:name><gtr:address><gtr:line1>Uganda Virus Research Institute</gtr:line1><gtr:line2>51-59 Nakiwogo Road, PO box 49</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Uganda</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/421AD70F-9A6E-48CE-9C42-6C508F1FBAD8"><gtr:id>421AD70F-9A6E-48CE-9C42-6C508F1FBAD8</gtr:id><gtr:name>Eastern Virginia Medical School (EVMS)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1EC5A569-85E9-44B3-AD1F-049F1003C9C6"><gtr:id>1EC5A569-85E9-44B3-AD1F-049F1003C9C6</gtr:id><gtr:name>University of Barcelona</gtr:name><gtr:address><gtr:line1>Universidad de Barcelona</gtr:line1><gtr:line2>Av Diagonal 647</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Spain</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A33EFB82-6D09-41B1-880E-842746F6062E"><gtr:id>A33EFB82-6D09-41B1-880E-842746F6062E</gtr:id><gtr:name>Medical Research Council of South Africa (MRC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/FC261FD5-B45D-4259-B992-37DB4AB8EBAC"><gtr:id>FC261FD5-B45D-4259-B992-37DB4AB8EBAC</gtr:id><gtr:firstName>Charles</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Lacey</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/42CE62AA-63C7-447E-8692-AE40469EF4A2"><gtr:id>42CE62AA-63C7-447E-8692-AE40469EF4A2</gtr:id><gtr:firstName>Anatoli</gtr:firstName><gtr:surname>Kamali</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/77677F12-115F-4B4D-A64E-7F4018BCA321"><gtr:id>77677F12-115F-4B4D-A64E-7F4018BCA321</gtr:id><gtr:firstName>Lorna</gtr:firstName><gtr:surname>Colquhoun</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E8F1F3EE-5A34-4726-A00A-4D1637B14147"><gtr:id>E8F1F3EE-5A34-4726-A00A-4D1637B14147</gtr:id><gtr:firstName>Benias</gtr:firstName><gtr:otherNames>J</gtr:otherNames><gtr:surname>Kavumura</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2F015310-79F3-4747-9285-123D265B4A63"><gtr:id>2F015310-79F3-4747-9285-123D265B4A63</gtr:id><gtr:firstName>Ute</gtr:firstName><gtr:surname>Jentsch</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3DA2B0B5-D348-4FDF-8B13-0FE6FE492EE9"><gtr:id>3DA2B0B5-D348-4FDF-8B13-0FE6FE492EE9</gtr:id><gtr:firstName>Helen</gtr:firstName><gtr:surname>Rees</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/47B97F2C-E1E7-4DBF-8C25-DF5C894A19A6"><gtr:id>47B97F2C-E1E7-4DBF-8C25-DF5C894A19A6</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Changalucha</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FF7C9766-B80F-4EBF-A578-E69BA282D59A"><gtr:id>FF7C9766-B80F-4EBF-A578-E69BA282D59A</gtr:id><gtr:firstName>Janet</gtr:firstName><gtr:otherNames>Howard</gtr:otherNames><gtr:surname>Darbyshire</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/636C5CFB-11D6-4C31-9B1B-3AE1E25BCA81"><gtr:id>636C5CFB-11D6-4C31-9B1B-3AE1E25BCA81</gtr:id><gtr:firstName>Ganapati</gtr:firstName><gtr:otherNames>Janardhana</gtr:otherNames><gtr:surname>Bhat</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2B944851-7705-4F79-819D-F8B04312F6F2"><gtr:id>2B944851-7705-4F79-819D-F8B04312F6F2</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>Nunn</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/81CD3257-D911-4957-BEDC-7C00741FCA8E"><gtr:id>81CD3257-D911-4957-BEDC-7C00741FCA8E</gtr:id><gtr:firstName>Leopold</gtr:firstName><gtr:surname>Zekeng</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/70F968F6-DDF4-4CEA-A81C-6779EE50080F"><gtr:id>70F968F6-DDF4-4CEA-A81C-6779EE50080F</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:surname>Pool</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3F774323-0469-4DDF-82AD-CFFC512C6285"><gtr:id>3F774323-0469-4DDF-82AD-CFFC512C6285</gtr:id><gtr:firstName>Richard John</gtr:firstName><gtr:surname>Hayes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7E3C0045-B615-48B0-B761-74896FEED7ED"><gtr:id>7E3C0045-B615-48B0-B761-74896FEED7ED</gtr:id><gtr:firstName>Sheena</gtr:firstName><gtr:surname>McCormack</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2D017551-27A1-4A44-9411-71B10309F61F"><gtr:id>2D017551-27A1-4A44-9411-71B10309F61F</gtr:id><gtr:firstName>Jonathan</gtr:firstName><gtr:otherNames>N</gtr:otherNames><gtr:surname>Weber</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C3838ED8-2C2E-4DEF-9C0D-7A7AC40F67C1"><gtr:id>C3838ED8-2C2E-4DEF-9C0D-7A7AC40F67C1</gtr:id><gtr:firstName>Nuala Mary</gtr:firstName><gtr:surname>McGrath</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2794362F-E19B-4728-BE22-BD650A1A1014"><gtr:id>2794362F-E19B-4728-BE22-BD650A1A1014</gtr:id><gtr:firstName>Gita</gtr:firstName><gtr:surname>Ramjee</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0100137"><gtr:id>EE474576-CEE6-4BC0-93F5-7775CC1871CB</gtr:id><gtr:title>Vaginal microbicides for the prevention of HIV transmission</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0100137</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2007-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2000000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>St George's University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MDP: Microbicides Development Programme</gtr:description><gtr:id>336845F2-A819-43B1-83D9-80B2B714A082</gtr:id><gtr:impact>Publications as listed.
Safety and efficacy data on PRO2000 vaginal gel, as reported in the Lancet paper (McCormack et al, 2010).
Use of mixed methods to collect and interpret adherence data as described in PlosOne papers (Pool et al, 2011).
Conference and workshop presentations to disseminate to the scientific audience and policy makers.
Webinar calls organised through the Global Campaign for Microbicides and the AIDS Vaccine Advocacy Coalition to reach community organisations.</gtr:impact><gtr:outcomeId>iMeNVFkdUZk-8</gtr:outcomeId><gtr:partnerContribution>Imperial College conducted experiments to better understand the mechanism of action of PRO2000, managed Phase I clinical trials, and the governance of the programme, the latter in partnership with MRC CTU.
Indevus provided product for the trials.
St George's conducted experiments to aid selection of candidate microbicides.
University of Barcelona coordinated the social science.
University of Southampton coordinated the community engagement.
LSHTM conducted mathematical modelling and assisted with the Phase III trial statistical analysis plan, as well as co-managing one of the clinical research centres.
The other partners managed clinical research centres in which clinical and social science studies were conducted.</gtr:partnerContribution><gtr:piContribution>Coordination of clinical studies and governance of programme, the latter in partnership with Imperial College. 
Data management, analysis and report writing for clinical studies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>FHI 360</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Hormonal contraception and risk of HIV acquistion: individual participant data analysis</gtr:description><gtr:id>7FB4A19C-2266-4645-935C-9C35FF1AFE8A</gtr:id><gtr:impact>An oral presentation at CROI 2014 and a manuscript which has been submitted. The analysis will be used by WHO when considering the next revision to their guidelines.</gtr:impact><gtr:outcomeId>546248de2fc527.82139755-1</gtr:outcomeId><gtr:partnerContribution>Import of the data and analysis using marginal structural models.</gtr:partnerContribution><gtr:piContribution>We provided data from the MDP301 dataset to the team at FHI as part of the individual participant data analysis to assess the association between hormonal contraception and the acquisition of HIV. As MDP301 was the largest dataset (over 8000 women) it was very influential. The Trial Statistician for MDP301 had to prepare the dataset for export.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of KwaZulu-Natal</gtr:collaboratingOrganisation><gtr:country>South Africa, Republic of</gtr:country><gtr:description>MDP: Microbicides Development Programme</gtr:description><gtr:id>17551B47-1E4C-4C27-8B44-F0D9A0A1E3ED</gtr:id><gtr:impact>Publications as listed.
Safety and efficacy data on PRO2000 vaginal gel, as reported in the Lancet paper (McCormack et al, 2010).
Use of mixed methods to collect and interpret adherence data as described in PlosOne papers (Pool et al, 2011).
Conference and workshop presentations to disseminate to the scientific audience and policy makers.
Webinar calls organised through the Global Campaign for Microbicides and the AIDS Vaccine Advocacy Coalition to reach community organisations.</gtr:impact><gtr:outcomeId>iMeNVFkdUZk-5</gtr:outcomeId><gtr:partnerContribution>Imperial College conducted experiments to better understand the mechanism of action of PRO2000, managed Phase I clinical trials, and the governance of the programme, the latter in partnership with MRC CTU.
Indevus provided product for the trials.
St George's conducted experiments to aid selection of candidate microbicides.
University of Barcelona coordinated the social science.
University of Southampton coordinated the community engagement.
LSHTM conducted mathematical modelling and assisted with the Phase III trial statistical analysis plan, as well as co-managing one of the clinical research centres.
The other partners managed clinical research centres in which clinical and social science studies were conducted.</gtr:partnerContribution><gtr:piContribution>Coordination of clinical studies and governance of programme, the latter in partnership with Imperial College. 
Data management, analysis and report writing for clinical studies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MRC/UVRI Uganda Research Unit on AIDS</gtr:collaboratingOrganisation><gtr:country>Uganda, Republic of</gtr:country><gtr:description>MDP: Microbicides Development Programme</gtr:description><gtr:id>03FD7E62-C429-4951-94F1-CD9EE1D157B5</gtr:id><gtr:impact>Publications as listed.
Safety and efficacy data on PRO2000 vaginal gel, as reported in the Lancet paper (McCormack et al, 2010).
Use of mixed methods to collect and interpret adherence data as described in PlosOne papers (Pool et al, 2011).
Conference and workshop presentations to disseminate to the scientific audience and policy makers.
Webinar calls organised through the Global Campaign for Microbicides and the AIDS Vaccine Advocacy Coalition to reach community organisations.</gtr:impact><gtr:outcomeId>iMeNVFkdUZk-12</gtr:outcomeId><gtr:partnerContribution>Imperial College conducted experiments to better understand the mechanism of action of PRO2000, managed Phase I clinical trials, and the governance of the programme, the latter in partnership with MRC CTU.
Indevus provided product for the trials.
St George's conducted experiments to aid selection of candidate microbicides.
University of Barcelona coordinated the social science.
University of Southampton coordinated the community engagement.
LSHTM conducted mathematical modelling and assisted with the Phase III trial statistical analysis plan, as well as co-managing one of the clinical research centres.
The other partners managed clinical research centres in which clinical and social science studies were conducted.</gtr:partnerContribution><gtr:piContribution>Coordination of clinical studies and governance of programme, the latter in partnership with Imperial College. 
Data management, analysis and report writing for clinical studies.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Eastern Virginia Medical School (EVMS)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Contraception Research and Development (CONRAD)</gtr:department><gtr:description>IPM Top Up</gtr:description><gtr:id>FA42FE8A-D375-4783-ACB6-6E3DC963FE99</gtr:id><gtr:impact>Conference abstracts and posters comparing the three different methods of collecting in the used applicators (daily, weekly or at the monthly visit).</gtr:impact><gtr:outcomeId>sPdLovyfQkd-2</gtr:outcomeId><gtr:partnerContribution>IPM is a not for profit product developer of microbicides. They provided financial support to MDP which is funded mainly through MRC/DFID with some support from EDCTP. IPM made comments on the protocol and provided financial support to enable the clinical research centres to enrol and follow particiaptns. IPM is committed to daily microbicides (as opposed to intermittent, coitally dependent dosing).</gtr:partnerContribution><gtr:piContribution>We drafted the protocol, CRFs, and documentation, designed and implemneted the local and combined database, completed initiation training with all clinical centres, organised shipments of gel with CONRAD, monitored through to close-out three of the five centres by the end of 2010, and held monthly Trial Management Group calls. We cleaned and closed the database, extracted and analysed data and coordinated the preparation of conference abstracts and posters.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Indevus Pharmaceuticals, Inc.</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>MDP: Microbicides Development Programme</gtr:description><gtr:id>EEA3123E-51B0-48ED-A6B3-60A5574F2217</gtr:id><gtr:impact>Publications as listed.
Safety and efficacy data on PRO2000 vaginal gel, as reported in the Lancet paper (McCormack et al, 2010).
Use of mixed methods to collect and interpret adherence data as described in PlosOne papers (Pool et al, 2011).
Conference and workshop presentations to disseminate to the scientific audience and policy makers.
Webinar calls organised through the Global Campaign for Microbicides and the AIDS Vaccine Advocacy Coalition to reach community organisations.</gtr:impact><gtr:outcomeId>iMeNVFkdUZk-2</gtr:outcomeId><gtr:partnerContribution>Imperial College conducted experiments to better understand the mechanism of action of PRO2000, managed Phase I clinical trials, and the governance of the programme, the latter in partnership with MRC CTU.
Indevus provided product for the trials.
St George's conducted experiments to aid selection of candidate microbicides.
University of Barcelona coordinated the social science.
University of Southampton coordinated the community engagement.
LSHTM conducted mathematical modelling and assisted with the Phase III trial statistical analysis plan, as well as co-managing one of the clinical research centres.
The other partners managed clinical research centres in which clinical and social science studies were conducted.</gtr:partnerContribution><gtr:piContribution>Coordination of clinical studies and governance of programme, the latter in partnership with Imperial College. 
Data management, analysis and report writing for clinical studies.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MDP: Microbicides Development Programme</gtr:description><gtr:id>37B3689B-9947-4B66-854C-3F1153C2FEBD</gtr:id><gtr:impact>Publications as listed.
Safety and efficacy data on PRO2000 vaginal gel, as reported in the Lancet paper (McCormack et al, 2010).
Use of mixed methods to collect and interpret adherence data as described in PlosOne papers (Pool et al, 2011).
Conference and workshop presentations to disseminate to the scientific audience and policy makers.
Webinar calls organised through the Global Campaign for Microbicides and the AIDS Vaccine Advocacy Coalition to reach community organisations.</gtr:impact><gtr:outcomeId>iMeNVFkdUZk-1</gtr:outcomeId><gtr:partnerContribution>Imperial College conducted experiments to better understand the mechanism of action of PRO2000, managed Phase I clinical trials, and the governance of the programme, the latter in partnership with MRC CTU.
Indevus provided product for the trials.
St George's conducted experiments to aid selection of candidate microbicides.
University of Barcelona coordinated the social science.
University of Southampton coordinated the community engagement.
LSHTM conducted mathematical modelling and assisted with the Phase III trial statistical analysis plan, as well as co-managing one of the clinical research centres.
The other partners managed clinical research centres in which clinical and social science studies were conducted.</gtr:partnerContribution><gtr:piContribution>Coordination of clinical studies and governance of programme, the latter in partnership with Imperial College. 
Data management, analysis and report writing for clinical studies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Southampton</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MDP: Microbicides Development Programme</gtr:description><gtr:id>BDAB90D1-6A0C-4AF2-AEE6-227915911F84</gtr:id><gtr:impact>Publications as listed.
Safety and efficacy data on PRO2000 vaginal gel, as reported in the Lancet paper (McCormack et al, 2010).
Use of mixed methods to collect and interpret adherence data as described in PlosOne papers (Pool et al, 2011).
Conference and workshop presentations to disseminate to the scientific audience and policy makers.
Webinar calls organised through the Global Campaign for Microbicides and the AIDS Vaccine Advocacy Coalition to reach community organisations.</gtr:impact><gtr:outcomeId>iMeNVFkdUZk-4</gtr:outcomeId><gtr:partnerContribution>Imperial College conducted experiments to better understand the mechanism of action of PRO2000, managed Phase I clinical trials, and the governance of the programme, the latter in partnership with MRC CTU.
Indevus provided product for the trials.
St George's conducted experiments to aid selection of candidate microbicides.
University of Barcelona coordinated the social science.
University of Southampton coordinated the community engagement.
LSHTM conducted mathematical modelling and assisted with the Phase III trial statistical analysis plan, as well as co-managing one of the clinical research centres.
The other partners managed clinical research centres in which clinical and social science studies were conducted.</gtr:partnerContribution><gtr:piContribution>Coordination of clinical studies and governance of programme, the latter in partnership with Imperial College. 
Data management, analysis and report writing for clinical studies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International Partnership for Microbicides (IPM)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>IPM Top Up</gtr:description><gtr:id>8D18F035-74AB-4E74-9354-4A238B7A6EBA</gtr:id><gtr:impact>Conference abstracts and posters comparing the three different methods of collecting in the used applicators (daily, weekly or at the monthly visit).</gtr:impact><gtr:outcomeId>sPdLovyfQkd-1</gtr:outcomeId><gtr:partnerContribution>IPM is a not for profit product developer of microbicides. They provided financial support to MDP which is funded mainly through MRC/DFID with some support from EDCTP. IPM made comments on the protocol and provided financial support to enable the clinical research centres to enrol and follow particiaptns. IPM is committed to daily microbicides (as opposed to intermittent, coitally dependent dosing).</gtr:partnerContribution><gtr:piContribution>We drafted the protocol, CRFs, and documentation, designed and implemneted the local and combined database, completed initiation training with all clinical centres, organised shipments of gel with CONRAD, monitored through to close-out three of the five centres by the end of 2010, and held monthly Trial Management Group calls. We cleaned and closed the database, extracted and analysed data and coordinated the preparation of conference abstracts and posters.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Barcelona (UB)</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>MDP: Microbicides Development Programme</gtr:description><gtr:id>805F9851-86E1-4999-B344-FFF5EFFEC618</gtr:id><gtr:impact>Publications as listed.
Safety and efficacy data on PRO2000 vaginal gel, as reported in the Lancet paper (McCormack et al, 2010).
Use of mixed methods to collect and interpret adherence data as described in PlosOne papers (Pool et al, 2011).
Conference and workshop presentations to disseminate to the scientific audience and policy makers.
Webinar calls organised through the Global Campaign for Microbicides and the AIDS Vaccine Advocacy Coalition to reach community organisations.</gtr:impact><gtr:outcomeId>iMeNVFkdUZk-9</gtr:outcomeId><gtr:partnerContribution>Imperial College conducted experiments to better understand the mechanism of action of PRO2000, managed Phase I clinical trials, and the governance of the programme, the latter in partnership with MRC CTU.
Indevus provided product for the trials.
St George's conducted experiments to aid selection of candidate microbicides.
University of Barcelona coordinated the social science.
University of Southampton coordinated the community engagement.
LSHTM conducted mathematical modelling and assisted with the Phase III trial statistical analysis plan, as well as co-managing one of the clinical research centres.
The other partners managed clinical research centres in which clinical and social science studies were conducted.</gtr:partnerContribution><gtr:piContribution>Coordination of clinical studies and governance of programme, the latter in partnership with Imperial College. 
Data management, analysis and report writing for clinical studies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Manhi?a Health Research Centre (CISM)</gtr:collaboratingOrganisation><gtr:country>Mozambique, Republic of</gtr:country><gtr:description>MDP: Microbicides Development Programme</gtr:description><gtr:id>5C92882D-6F3D-414F-9B46-58AC328C9B91</gtr:id><gtr:impact>Publications as listed.
Safety and efficacy data on PRO2000 vaginal gel, as reported in the Lancet paper (McCormack et al, 2010).
Use of mixed methods to collect and interpret adherence data as described in PlosOne papers (Pool et al, 2011).
Conference and workshop presentations to disseminate to the scientific audience and policy makers.
Webinar calls organised through the Global Campaign for Microbicides and the AIDS Vaccine Advocacy Coalition to reach community organisations.</gtr:impact><gtr:outcomeId>iMeNVFkdUZk-10</gtr:outcomeId><gtr:partnerContribution>Imperial College conducted experiments to better understand the mechanism of action of PRO2000, managed Phase I clinical trials, and the governance of the programme, the latter in partnership with MRC CTU.
Indevus provided product for the trials.
St George's conducted experiments to aid selection of candidate microbicides.
University of Barcelona coordinated the social science.
University of Southampton coordinated the community engagement.
LSHTM conducted mathematical modelling and assisted with the Phase III trial statistical analysis plan, as well as co-managing one of the clinical research centres.
The other partners managed clinical research centres in which clinical and social science studies were conducted.</gtr:partnerContribution><gtr:piContribution>Coordination of clinical studies and governance of programme, the latter in partnership with Imperial College. 
Data management, analysis and report writing for clinical studies.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>London School of Hygiene and Tropical Medicine (LSHTM)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MDP: Microbicides Development Programme</gtr:description><gtr:id>46A8A446-5E5E-490E-8248-D5F6E305C874</gtr:id><gtr:impact>Publications as listed.
Safety and efficacy data on PRO2000 vaginal gel, as reported in the Lancet paper (McCormack et al, 2010).
Use of mixed methods to collect and interpret adherence data as described in PlosOne papers (Pool et al, 2011).
Conference and workshop presentations to disseminate to the scientific audience and policy makers.
Webinar calls organised through the Global Campaign for Microbicides and the AIDS Vaccine Advocacy Coalition to reach community organisations.</gtr:impact><gtr:outcomeId>iMeNVFkdUZk-3</gtr:outcomeId><gtr:partnerContribution>Imperial College conducted experiments to better understand the mechanism of action of PRO2000, managed Phase I clinical trials, and the governance of the programme, the latter in partnership with MRC CTU.
Indevus provided product for the trials.
St George's conducted experiments to aid selection of candidate microbicides.
University of Barcelona coordinated the social science.
University of Southampton coordinated the community engagement.
LSHTM conducted mathematical modelling and assisted with the Phase III trial statistical analysis plan, as well as co-managing one of the clinical research centres.
The other partners managed clinical research centres in which clinical and social science studies were conducted.</gtr:partnerContribution><gtr:piContribution>Coordination of clinical studies and governance of programme, the latter in partnership with Imperial College. 
Data management, analysis and report writing for clinical studies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Zambia</gtr:collaboratingOrganisation><gtr:country>Zambia, Republic of</gtr:country><gtr:description>MDP: Microbicides Development Programme</gtr:description><gtr:id>8D8FB4A5-D84F-4E4E-8E61-EF26200E12BE</gtr:id><gtr:impact>Publications as listed.
Safety and efficacy data on PRO2000 vaginal gel, as reported in the Lancet paper (McCormack et al, 2010).
Use of mixed methods to collect and interpret adherence data as described in PlosOne papers (Pool et al, 2011).
Conference and workshop presentations to disseminate to the scientific audience and policy makers.
Webinar calls organised through the Global Campaign for Microbicides and the AIDS Vaccine Advocacy Coalition to reach community organisations.</gtr:impact><gtr:outcomeId>iMeNVFkdUZk-6</gtr:outcomeId><gtr:partnerContribution>Imperial College conducted experiments to better understand the mechanism of action of PRO2000, managed Phase I clinical trials, and the governance of the programme, the latter in partnership with MRC CTU.
Indevus provided product for the trials.
St George's conducted experiments to aid selection of candidate microbicides.
University of Barcelona coordinated the social science.
University of Southampton coordinated the community engagement.
LSHTM conducted mathematical modelling and assisted with the Phase III trial statistical analysis plan, as well as co-managing one of the clinical research centres.
The other partners managed clinical research centres in which clinical and social science studies were conducted.</gtr:partnerContribution><gtr:piContribution>Coordination of clinical studies and governance of programme, the latter in partnership with Imperial College. 
Data management, analysis and report writing for clinical studies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Eastern Virginia Medical School (EVMS)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Contraception Research and Development (CONRAD)</gtr:department><gtr:description>CONRAD (USAID funding) Top Up</gtr:description><gtr:id>0BCCEE10-7AEB-47D4-B68F-DC5546FF1A96</gtr:id><gtr:impact>The Top Up analysis has been presented at conferences and a manuscript is being prepared. Five centres in five countries in Sub-Saharan Africa took part in this study of daily gel.</gtr:impact><gtr:outcomeId>feGh4RbC91V-1</gtr:outcomeId><gtr:partnerContribution>CONRAD/East VIrginia Medical School supplied placebo gel for Top Up and funded one of the MDO clinical partners (University of Zambia) to conduct the study.</gtr:partnerContribution><gtr:piContribution>We drafted the protocol, CRFs, and documentation, designed and implemneted the local and combined database, completed initiation training with all clinical centres, organised shipments of gel with CONRAD, monitored through to close-out three of the five centres by the end of 2010, and held monthly Trial Management Group calls. We closed the database and extracted the final analysis files and coordinated the preparation of conference abstracts and poster presentations.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Eastern Virginia Medical School (EVMS)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Contraception Research and Development (CONRAD)</gtr:department><gtr:description>Microbicides Development Programme (MDP) and CONRAD tenofovir project</gtr:description><gtr:id>84F905E8-D539-4A4E-A1D3-31F8561EE318</gtr:id><gtr:impact>Full funding application to EDCTP 15th March 2016, but not funded.</gtr:impact><gtr:outcomeId>54623574017df4.16347308-1</gtr:outcomeId><gtr:partnerContribution>CONRAD invited Professor Sheena McCormack to develop research proposals for CONRAD's Microbicide APS Objective 1 (MAPS1) which was successfully funded</gtr:partnerContribution><gtr:piContribution>Our research team developed research proposals to conduct a phase II clinical trial of tenofovir gel in either vaginal ring or tablet form, and an open-label wait listed design of tenofovir gel with Microbicides Development Programme partners in Uganda and Mozambique. 

Funding application currently being drafted for submission to EDCTP by 15th March 2016: 'A pragmatic, randomised open-label wait-listed trial to evaluate the effectiveness of tenofovir to reduce the risk of HIV acquisition among women involved in transactional and commercial sex in Mozambique, Rwanda, Tanzania and Uganda.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International Partnership for Microbicides (IPM)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>IPM Close Out</gtr:description><gtr:id>78C0793D-A55D-4EB7-BB9E-A2F959285EF9</gtr:id><gtr:impact>Close out monitoring reports.
The collaboration is multi-disciplinary (clinical, biostatisticians, data scientists, trial managers, product developers) but the same disciplines are represented in MDP and IPM other than the industry partner (Endo) in MDP.</gtr:impact><gtr:outcomeId>oWD9cCmaar9-1</gtr:outcomeId><gtr:partnerContribution>Advice on the appointment of a commercial research organistation to assist with the completion of trial close-out visits and archiving.</gtr:partnerContribution><gtr:piContribution>We designed the trial, drafted the protocol, CRFs, other documentation including the analysis plan, designed and implemented the database locally and centrally, wrote the necessary statsitical programmes, completed training, on site and central monitoring, analyses, statistical reports x3, drafted and submitted manuscript for peer-review, managed communications, oversaw the management of the award completing quarterly reports to donors.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of the Witwatersrand</gtr:collaboratingOrganisation><gtr:country>South Africa, Republic of</gtr:country><gtr:department>Reproductive Health and HIV Research Unit (RHRU) Witwatersrand</gtr:department><gtr:description>MDP: Microbicides Development Programme</gtr:description><gtr:id>B2832461-B34B-404F-93CD-79BE714D98EC</gtr:id><gtr:impact>Publications as listed.
Safety and efficacy data on PRO2000 vaginal gel, as reported in the Lancet paper (McCormack et al, 2010).
Use of mixed methods to collect and interpret adherence data as described in PlosOne papers (Pool et al, 2011).
Conference and workshop presentations to disseminate to the scientific audience and policy makers.
Webinar calls organised through the Global Campaign for Microbicides and the AIDS Vaccine Advocacy Coalition to reach community organisations.</gtr:impact><gtr:outcomeId>iMeNVFkdUZk-11</gtr:outcomeId><gtr:partnerContribution>Imperial College conducted experiments to better understand the mechanism of action of PRO2000, managed Phase I clinical trials, and the governance of the programme, the latter in partnership with MRC CTU.
Indevus provided product for the trials.
St George's conducted experiments to aid selection of candidate microbicides.
University of Barcelona coordinated the social science.
University of Southampton coordinated the community engagement.
LSHTM conducted mathematical modelling and assisted with the Phase III trial statistical analysis plan, as well as co-managing one of the clinical research centres.
The other partners managed clinical research centres in which clinical and social science studies were conducted.</gtr:partnerContribution><gtr:piContribution>Coordination of clinical studies and governance of programme, the latter in partnership with Imperial College. 
Data management, analysis and report writing for clinical studies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Manhi?a Health Research Centre (CISM)</gtr:collaboratingOrganisation><gtr:country>Mozambique, Republic of</gtr:country><gtr:description>CISM, Mozambique (Mo-Jo)</gtr:description><gtr:id>405F4476-3A51-4404-84B1-B4B7CF2326B7</gtr:id><gtr:impact>Completed Feasibility Study in Mozambique (published)
Completed Pilot Study (Top Up) and gained multi-centre experience as a result.
South to South networking and capacity building facilitated through RHRU in Johannesburg for the Feasibility Study component.
Conference abstracts and manuscript in preparation.</gtr:impact><gtr:outcomeId>ZJjKjyRBNVV-1</gtr:outcomeId><gtr:partnerContribution>This partnership was facilitated through an EDCTP award. CISM contributed through the work completed under this award (see outputs).</gtr:partnerContribution><gtr:piContribution>Provision of research tools (protocol, CRFs, database), assistance with training and monitoring. Implementation of the first ever microbicide study in Mozambique (Top Up). Coordination and support for analyses.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council of South Africa (MRC)</gtr:collaboratingOrganisation><gtr:country>South Africa, Republic of</gtr:country><gtr:description>MDP: Microbicides Development Programme</gtr:description><gtr:id>D4A4F226-ABB5-4A48-A2CE-4BA957B42B3C</gtr:id><gtr:impact>Publications as listed.
Safety and efficacy data on PRO2000 vaginal gel, as reported in the Lancet paper (McCormack et al, 2010).
Use of mixed methods to collect and interpret adherence data as described in PlosOne papers (Pool et al, 2011).
Conference and workshop presentations to disseminate to the scientific audience and policy makers.
Webinar calls organised through the Global Campaign for Microbicides and the AIDS Vaccine Advocacy Coalition to reach community organisations.</gtr:impact><gtr:outcomeId>iMeNVFkdUZk-7</gtr:outcomeId><gtr:partnerContribution>Imperial College conducted experiments to better understand the mechanism of action of PRO2000, managed Phase I clinical trials, and the governance of the programme, the latter in partnership with MRC CTU.
Indevus provided product for the trials.
St George's conducted experiments to aid selection of candidate microbicides.
University of Barcelona coordinated the social science.
University of Southampton coordinated the community engagement.
LSHTM conducted mathematical modelling and assisted with the Phase III trial statistical analysis plan, as well as co-managing one of the clinical research centres.
The other partners managed clinical research centres in which clinical and social science studies were conducted.</gtr:partnerContribution><gtr:piContribution>Coordination of clinical studies and governance of programme, the latter in partnership with Imperial College. 
Data management, analysis and report writing for clinical studies.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>AIDS Impact Conference, 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4D2EA778-4C9E-4B45-A356-F6C42036C026</gtr:id><gtr:impact>Authors: Mitzy Gafos, Robert Pool, Sheena McCormack, Jonathan Elford
Title: Exploring women's use of microbicides without their partner's knowledge: experiences from a predominantly rural area of KwaZulu-Natal, South Africa
Conference: AIDS Impact
Dates: 29th Sept to 2nd Oct 2013
Location: Barcelona, Spain
Presented to approximately 75 people

Academic discussion about presentation of relevance to manuscript development</gtr:impact><gtr:outcomeId>Yf7oFTK9L2Y</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.aidsimpact.com/2013/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CHAARM video filming, 28th April 2014</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D9B72828-D019-42D0-A436-55D3DF785405</gtr:id><gtr:impact>Prof. Sheena McCormack was filmed for the video which has been posted at http://chaarm.eu/content/newsroom
An explanatory video has been produced with the aim of presenting the CHAARM project and its main goal. It explains what are microbicides and it shows why is important to develop alternative prevention methods, such as new combination of microbicides, for controlling the risk of HIV infection. Video posted 25th July 2014.

This film aimed to increase the profile of microbicides in Europe.</gtr:impact><gtr:outcomeId>54562033c03330.47210693</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://chaarm.eu/content/newsroom</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Microbicide Media Communications Initiative (MMCI)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>33AF28F1-060A-4F0B-86AC-48A85E67F74A</gtr:id><gtr:impact>MMCI host regular teleconferences with advocates. I provide regular updates to the international group of approximately 100 members on teleconferences.

Developed a series of key messages in advance of the AIDS conference 2012.</gtr:impact><gtr:outcomeId>Qh2BzU4pWHA</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dr. Catherine Montgomery presented 'Events, Looks, Data: Friction and Lubrication' at a meeting: New Methodologies for Interdisciplinarity in HIV and Related Health Fields, 25th June 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0CFA1C7C-AA81-4AD0-ACAE-ED8FF930A48A</gtr:id><gtr:impact>Dr. Catherine Montgomery presented: 'Events, Looks, Data: Friction and Lubrication in Clinical Trials', referring to MDP301 trial data in her presentation.

Attended by 35 people

-</gtr:impact><gtr:outcomeId>5459014c574b74.49550069</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NY Times - Donald McNeil and Celia Dugger</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8C1970CE-54FF-4FC3-97DC-59A21487058A</gtr:id><gtr:impact>I was interviewed by Donald and Celia following release of the CAPRISA 004 result, during the AIDS conference and a few weeks later on the phone.

Donald McNeil was very appreciative of my explanation of the confidence interval.
I had the opportunity to explain to both journalists the challenges ahead for implementation, the complexity of the dual dosing regimen in CAPRISA, and the closing gap to collect placebo-controlled comparison of a single dose of tenofovir applied prior to sex.</gtr:impact><gtr:outcomeId>g7WcRHytaUE</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>US Institute of Medicine Review of HIV prevention trials</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>E1150FFB-734D-41E6-8465-1DAC333F13EA</gtr:id><gtr:impact>I gave a talk with slides to the IoM panel which is open to the public. The panel members asked several questions and were particularly intersted in our preparatory work for the Phase III microbicide trial, and the integrated social science. They asked especially about the triangulation of several methods to assess adherence to gel.

The IoM recommendations mirrored the work already completed in MDP ie collection of cohort data to accurately assess HIV incidence, careful mapping of comunities, behaviours and attitudes, piloting the gel and trial tools, triangulating different measurements of adherence.</gtr:impact><gtr:outcomeId>F9CmvWYw4DT</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ASSHH Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>64BCDA22-7AFE-46E4-A106-1D9630EBBB6E</gtr:id><gtr:impact>Authors: Mitzy Gafos, Robert Pool, Sheena McCormack, Jonathan Elford
Title: Interpreting the interplay between biomedical knowledge and communication 
Conference title: Association for the Social Sciences and Humanities in HIV (ASSHH)
Dates: 7th to 10th July 2013
Location: Paris, France
Presented to audience of approximately 15 people

Made contact with two relevant researchers for future collaborations</gtr:impact><gtr:outcomeId>EXeTCvn7vTQ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://asshhconference.org/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Institute of Medical Research, Papua New Guinea</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D5F3752B-491F-4485-B470-E7A45864A327</gtr:id><gtr:impact>The IMR of Papua New Guinea are conducting microbicide feasibility work. Two MDP representatives presented findings from the MDP 301 trial to an audience of approximately 40 scientists and talked at a workshop of approximately 15 social scientists on social science techniques in HIV prevention research.

Informed their research plans.</gtr:impact><gtr:outcomeId>X3x6f3bH6D3</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CROI conference, 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9EA7CF17-F3FC-4896-B320-794CEBBF2936</gtr:id><gtr:impact>Presented to an audience of approximately 300 people.
CROI conference, 3-6 March 2013, Atlanta.
Title: Hormonal Contraception and Risk of HIV: An analysis of MDP 301
Authors:Angela Crook et al

Presentation was discussed at the conference press conference - discussion fed into development of a manuscript</gtr:impact><gtr:outcomeId>SCnMmLwP8Xb</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>South African AIDS Conferece</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8B9E8AC4-A23E-4948-9BAB-1E687DB68658</gtr:id><gtr:impact>Authors: Kristin Fladseth, Mitzy Gafos, Marie-Louise Newell, Nuala McGrath
Title: More equitable gender norms are associated with higher levels of condom use at last sex among HIV+ve men and women: rural KwaZulu-Natal, South Africa
Conference: South African AIDS Conference
Date:18th - 21st June 2013
Location: Durban, South Africa

Scientific discussion relevant for manuscript development</gtr:impact><gtr:outcomeId>BRbFEFaajVK</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.saaids.co.za/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EDCTP HIV Stakeholders meeting, Sep 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>878B277F-9E4B-49ED-B74F-963DBF3AD877</gtr:id><gtr:impact>There were about 100 delegates from Africa, Europe and the US that attended this meeting. The majority were senior and influential academics or from normative agencies.

I am uniquely privileged to be working in microbicides, vaccines and PrEP to reduce the risk of HIV, and across the spectrum of product development from Phase I through to implementation. This was a excellent opportunity to provide a perspective balanced by the breadth and depth of my clinical trial experience.</gtr:impact><gtr:outcomeId>LGPvQqb1UEn</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.edctp.org</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Institute of Development Studies discussion forum on urbanisation, gender and health</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E780CEFE-B592-4FD6-9B3C-3EAC4C0F37B8</gtr:id><gtr:impact>This was an online three day discussion from 29-31 Jan 2013 involving approximately 40 people working in research, policy development and service delivery - with a focus on Kenya and South Africa. IDS will produce a report of the discussion for DFID.

Made contact with people working in a range of organizations mainly in South Africa.

Oct 2013 - update - a report entitled &amp;quot;Urbanisation, gender and health&amp;quot; has now been published and is available at http://interactions.eldis.org/</gtr:impact><gtr:outcomeId>ihbZ2BuXiFr</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://interactions.eldis.org/</gtr:url><gtr:year>2010,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Prof. Helen Rees webinar for AVAC on HC and HIV during which she referenced MDP data,10th March 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>51B327FF-F10C-4B6B-B393-8106DE641F47</gtr:id><gtr:impact>-</gtr:impact><gtr:outcomeId>5458c320ea2632.15957229</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dr. Mitzy Gafos attendance at the AVAC Communications Working Groups meeting on 30th April and 1st May, New York</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>209D2C71-2F46-4AEA-91E1-4E114078CEEC</gtr:id><gtr:impact>Discuss communications needs of HIV prevention

Inform communication priorities for coming year</gtr:impact><gtr:outcomeId>5458fba05cf185.47421455</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited speaker for CHAARM symposium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A5A61364-723D-4AF4-A0CA-C708AB62C677</gtr:id><gtr:impact>About 200 people attended this symposium which was part of the European AIDS Clinical Society 2013 programme. I was invited to outline the Current status of Microbicide Trials.

The symposium sparked interest from the media leading to interviews.</gtr:impact><gtr:outcomeId>g6VHsbyQwvL</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:url>http://chaarm.eu/content/newsroom</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dr. Catherine Montgomery presented at a seminar on interventional trials in developing countries: Who is the 'trial community' and why does it matter? 7th April 2014, University College London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>2CA015B0-96FB-4BC3-A740-15815383CDE9</gtr:id><gtr:impact>Dr. Montgomery presented anthropological work from her PhD on the successes and challenges of working in Mazabuka, broadly covering:
 
- the MDP philosophy of capacity building, incl. local ownership of data, training, etc.
- the challenges of bringing men on board 
- rumours and problems with misreporting at the end of the trial
- the trial as an intervention in its own right: how not just trial participants, but staff, investigators and communities at many levels can be changed in the process of conducting research
- presented also the capacity building outputs of MDP to present (numbers of higher degrees etc)

Seminar aimed at clinical academics in medicine with the aim to provide them with practical advice and educate.</gtr:impact><gtr:outcomeId>5458cbe3115c42.66601467</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Microbicides lecture, AIDS module, 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F91837F2-F28D-4788-BA2D-CCAA1233EBB8</gtr:id><gtr:impact>This talk is embedded in the AIDS 3174 module offered by the LSHTM to their post-graduate students.

Not all the audience had heard of microbicides at the outset, and very few were aware of the current status of the trials, or the relevance of the oral PrEP studies to development of these topical agents.</gtr:impact><gtr:outcomeId>J3auR4SoM8Z</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dr. Mitzy Gafos presentation to UK-CAB (HIV Treatment Advocates Network): The Changing Landscape of Biomedical HIV Prevention Research, 25th April 2014, Birkbeck College, London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E829C853-6494-458E-8EBB-6A6D3BE6057F</gtr:id><gtr:impact>The meeting had 26 attendees, a third of whom came from outside London.
UK-CAB HIV treatment advocates network.
CAB 50: Looking backwards, moving forward

Feedback from Mitzy's session was rated excellent by over 50% and good by the rest. Audience feedback was that the presentation was good, engaging and that it enhanced their understanding.



Audience reported an improvement to their understanding following Mitzy's presentation</gtr:impact><gtr:outcomeId>5458cde1354ae0.46670399</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.ukcab.net/meetings/presentations/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Inaugural lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>31A92983-59D8-409A-A28A-C57D04FB8B8F</gtr:id><gtr:impact>About 200 people from a range of disciplines and including the general public and school children attended and it was an opportunity to raise awareness of the ongoing HIV epidemic, the dramatic advances in biomedical interventions for the prevention of HIV and the importance of behaviour.

The lecture was videoed and posted on YouTube and tweeted.</gtr:impact><gtr:outcomeId>CCbPswDJyWf</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dissemination of MDP301 results to the media</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:id>87184125-D78D-4709-93E0-0555962734B4</gtr:id><gtr:impact>MRC Press Office coordinated the approach to journalists they work closely with and who are known to be interested in HIV/AIDS. I briefly described the results during a telephone interview and answered questions.

This interaction led to a series of well written balanced articles on the day of release, 14th December 2009.
Unfortunately, the coverage on the internet from a Zambian journalist a week later was inaccurate and sensational. This was very difficult to control and quickly escalated as it was picked up by newspapers and radio stations in more than one country in Africa, which gave the accusations credibility.</gtr:impact><gtr:outcomeId>pWuwhq83zKq</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Advocates Guide to the R4P Conference - webinar, 6th Nov. 2014</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9B546E45-C8B0-408E-8EBE-55B1FB3EC5C3</gtr:id><gtr:impact>The webinar was organised to provide feedback on R4P Conference, the first international HIV prevention conference to bring vaccines, microbicides and PREP together. I was asked to speak specifically on the take home messages regarding prevention for gay men in Europe following the iPerGay and PROUD announcements. These two trials reported early due to interim analyses demonstrating that PrEP was highly effective in reducing the risk of HIV in an event driven regimen (iPerGay) and taking acccount of any change in risk behaviours (PROUD). 
There was also feedback regarding a number of Good Participatory Practice presentations after which I was able to make the point that Community Engagement has always been at the heart of preparing for large HIV prevention trials.

I was emailed after the webinar by researchers and Communtiy Advocates who agreed with the points I had made.</gtr:impact><gtr:outcomeId>545a6522d816a2.96754633</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NAT meeting - Precious Lunga</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>F51FD82C-24F0-4F7C-9DA6-69F56B2D8B8D</gtr:id><gtr:impact>30 people attended. Precious gave a 15m talk describing our work in MDP incuding documentation of the challenges faced by women in Africa with respect to HIV testing and the positive reception of gel by women and their partners. There were a lot of questions.

Nothing of note, but some myths about gel were dispelled - eg that women from countries where dry sex was the practice will not like using gel (they do), and that women would likely hide gel use from their partners (they don't).</gtr:impact><gtr:outcomeId>eL9mdytH3TR</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Prof. Robin Shattock presented at the All-Party Parliamentary Group meeting focussed on AIDS, TB and Malaria, 25th Feb 2014</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CBF7B61B-97FA-4FBA-8880-3EF7B33BA464</gtr:id><gtr:impact>Professor Robin Shattock, Faculty of Medicine, Department of Medicine, Imperial College. Chairman of Mucosal infection and immunity and member of IAVI's Scientific Advisory Committee. Prof. Shattock addressed resistance to ARVs, therapeutic vaccines, the role of PrEP and the development of preventive vaccines.



Prof. Robin Shattock presented the challenges with resistance to ARVs which led on to discussions about why additional prevention options including microbicides and vaccines are needed. Slides on the UK HIV Resistance Database were presented also. Greater understanding gained by the APPG.</gtr:impact><gtr:outcomeId>5458c25eee5e30.02705724</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:url>http://www.lstmliverpool.ac.uk/events/february-2014/25-feb-all-party-parliamentary-group-on-malaria-and-neglected-tropical-diseases-meeting</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NAM/AVAC PrEp workshop</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>451284E4-A15C-45EC-BD16-FC7971B52DCF</gtr:id><gtr:impact>Through questions, I was able to point out to this mixed audience which included civil society and media, the challenge of rolling out anti-retroviral drugs for prevention when we are failing to meet the needs of positive individuals in sub-Saharn Africa, and that the vast majority of women in this setting are not at risk every day and unlikely to want to take a pill a day to protect them from a much less frequent risk of acquiring HIV.

During the breaks it was clear from feedback that several members of the audience were not previously aware of the needs of the target population, and challenges of roll-out.</gtr:impact><gtr:outcomeId>YW7qnzW9hKA</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Stakeholder consultation in Zambia</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>F8F7DBDF-716E-47D1-8F42-775954156F2E</gtr:id><gtr:impact>Following the accusations against the research team in Zambia, the Director of Public Health requested a public consultation inviting the local Chiefs, participants, Community Advisory Group members, the media, researchers and other stakeholders to hear the results of both MDP301 and the preceding HPTN035 microbicide trial studying PRO2000. I helped the local team to prepare for this, attended in the audience and answered questions.

Confirmation that there was a need and support for further microbicide research in Zambia.
The political situation was already complicated with no Pharmacy Board in place following a change in government in 2008, and the Permanent Secretary of Health under investigation for corruption.
This meeting was a turning point, but nonetheless approval to conduct further research continued to be witheld for other prevention initiatives, including our own. Whilst the other research groups have abandoned their plans, MDP remained in order to demonstrate microbicide research was still possible, and approval for the Top Up study of placebo gel materialised at the end of 2010.</gtr:impact><gtr:outcomeId>LhxV9XEFHDX</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>National AIDS Manual/AIDS Vaccine Advoacy Coalition Webinar on Microbicides</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D86B6292-DD36-4B40-9179-4980DC76C804</gtr:id><gtr:impact>About 80 people attended this webinar.

The slides and audio are available on the NAM and AVAC websites.</gtr:impact><gtr:outcomeId>AjPKBe5sx48</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.avac.org/ht/display/EventDetails/i/49094/TPL/MatDetails/pid/351</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Consultation on Standards of Prevention, Kampala</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>79CE6AE0-FEA1-4382-ABE3-E2AFF685D7F2</gtr:id><gtr:impact>My talk described the different ways in which MDP partners consulted key stakeholders in order to decide what the most appropriate standard of care should be locally. 
Presentation available on request.

The representative from the SA competent authority stated that MDP had set the gold standard for consultation.</gtr:impact><gtr:outcomeId>hGkwGKqo88h</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Feedback on Microbicides 2012 conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>A3D3BF2B-E8B1-4489-94A6-6DC86A1D5266</gtr:id><gtr:impact>Talk was given as part of regular seminar series to ~80 members of the clinical trials unit.

The seminar generated interested as there have been many exciting development in the field which impact other work within the unit.</gtr:impact><gtr:outcomeId>hSqqyQUweV2</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MTN 'Creating Desire for Microbicides' meeting, Arlington, USA, 13-14th May 2014</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>231D8B9F-F8C9-4E54-BC2A-808DE4042952</gtr:id><gtr:impact>Prof. Sheena McCormack invited to speak about PROUD at the meeting. Title of presentation: The PROUD Study: Creating desire for PrEP in the UK. This was an opportunity to promote the wait-listed design for assessment of products. The absence of placebo facilitates a more honest dialogue between participant and clinician, and means that participants are taking the product for themselves, not just for the study.

The audience understood why this design was the only one that could address the real-world effectiveness of PrEP in which participants were motivated to take a drug they knew would work, but less motivated to use condoms to reduce their risk of HIV.</gtr:impact><gtr:outcomeId>545620c1b9b956.77647922</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.mtnstopshiv.org/2014cd</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dissemination of MDP301 results to civil society groups</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>8E3FB85E-EBB3-47E9-93C7-A8B3FDF4DD8B</gtr:id><gtr:impact>I presented the results using a powerpoint presentation, and then took questions. The questions are typed in and facilitated by the conference chair.

Unfortunately the candidate microbicide, PRO2000, did not prevent HIV acquisition. This was very disappointing for the field as an earlier trial reported 30% protection. Although this was not statistically significant, it did raise hopes and expectations that MDP301 would be a positive result.</gtr:impact><gtr:outcomeId>qE2iqP5vty7</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dr. Mitzy Gafos presentation: Why New Methods? meeting: New Methodologies for Interdisciplinarity in HIV and Related Health Fields, Goldsmith's University, 25th June 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>71157EA0-DE2C-4C41-93B9-D4C196AAA2A7</gtr:id><gtr:impact>Presented methods used for data collection in microbicide and PrEP trials to data and advocated for the incorporation of new methods

Increased awareness of microbicide and PrEP studies and data tools applied</gtr:impact><gtr:outcomeId>5458fd54d64777.25353454</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.gold.ac.uk/sociology/research-centres/unitofplay/events/#d.en.62868</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>APPG HIV/AIDS - Sheena McCormack</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>3A792B88-DA73-4F9B-B799-6294DCC6ADED</gtr:id><gtr:impact>The session was well attended (~100) by MPs, civil society leadership and the general public, particularly students. There were several questions, with a focus on access which seemed premature.

There was an opportunity to reinforce the urgent need for prevention options, particularly for women in sub-Saharan Africa, and to ensure people understood that the researchers really did not know if the candidate microbicide would protect.</gtr:impact><gtr:outcomeId>AHSAv9FJaTC</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>41829957</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Programme Grant/DfID: Microbicides Development Programme</gtr:description><gtr:end>2010-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>405695E1-7F11-46EC-9C67-D28F60743CD7</gtr:id><gtr:outcomeId>V5TSj7uEtN4</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>31269</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>European and Developing Countries Clinical Trials Partnership</gtr:department><gtr:description>Networking/Capacity Building - Biomarkers</gtr:description><gtr:end>2013-01-02</gtr:end><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:fundingRef>IP.2007.33070.001</gtr:fundingRef><gtr:id>3C3E40BD-91DC-4FF0-9217-1BEE2BD3A2AF</gtr:id><gtr:outcomeId>aV1HsdY1GJe0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1687570</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>European and Developing Countries Clinical Trials Partnership</gtr:department><gtr:description>Clinical Trial/Capacity Building - MoJo</gtr:description><gtr:end>2010-12-02</gtr:end><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:fundingRef>CT.2005.33070.003</gtr:fundingRef><gtr:id>46AB2C54-C99D-4D69-A509-3731A7A5B1F6</gtr:id><gtr:outcomeId>bep1fM8Q5V70</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20904</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>European and Developing Countries Clinical Trials Partnership</gtr:department><gtr:description>Networking - Project Management</gtr:description><gtr:end>2008-04-02</gtr:end><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:id>2C94A9A9-0D1F-496F-BEA4-2ADF65C1258A</gtr:id><gtr:outcomeId>DTtM9FgAUHp0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2006-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>73455</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>European and Developing Countries Clinical Trials Partnership</gtr:department><gtr:description>Capacity Building - Tz Ug</gtr:description><gtr:end>2011-02-02</gtr:end><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:id>862F2B66-AD7C-4768-A53B-64F5BD2A8DEC</gtr:id><gtr:outcomeId>mNePMRW9Ktq0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Europrise Steering Committee</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>22AC8216-DA2C-4B9B-8470-C4E6D89E40AE</gtr:id><gtr:outcomeId>AhdQK7jo7SR</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Consultation on Standards of Care in HIV prevention trials</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:id>4064DB70-5216-4FA0-B837-8A3B30BBAC0F</gtr:id><gtr:outcomeId>hXiihyQweUw</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>WHO/UNAIDS ethical conduct of HIV prevention trials guidelines</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>8B3DDD5B-72A1-40D2-8921-A1AFAE03DE54</gtr:id><gtr:impact>The updated guidelines have been disseminated to research groups internationally and have influenced the dialogue between researchers and communities, facilitating joint ownership of large research projects even in resource limited settings.</gtr:impact><gtr:outcomeId>aQsobUypndU</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>WHO/UNAIDS ethical conduct of HIV prevention trials guidelines</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>5A404685-3DAA-4D34-B4D3-F9C9A53D1DA6</gtr:id><gtr:impact>Published UNAIDS 2008</gtr:impact><gtr:outcomeId>ELDJy4NMNFZ</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>FHI 360 Male Engagement in Microbicides</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:id>69554BAD-5F23-44CE-B682-00046DFF41B0</gtr:id><gtr:outcomeId>HJhvsP9YGnJ</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type><gtr:url>http://pdf.usaid.gov/pdf_docs/pa00k11w.pdf</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Good Participatory Practice Guidelines: case studies</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:id>943B9BDA-C147-4AF8-94C2-092F7C09BCE3</gtr:id><gtr:impact>Shared to research staff as lessons to improve implementation of GPP</gtr:impact><gtr:outcomeId>FZdEeAwnmam</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://www.avac.org/implementation-tools</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>IAPAC Consensus Statement, 2013</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>09495EC8-020C-432D-9AD3-F2FAE506AB72</gtr:id><gtr:outcomeId>CiryYKYQUZC</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Good Participatory Practice Guideline</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>BFB9649E-BEE7-4729-8917-66B86F7801A5</gtr:id><gtr:impact>The methods we developed for community engagement made use of participatory methodology. This has not previously been used in HIV prevention trials to our knowledge. It provided a mechanism for feedback that led to improvement in recruitment, retention and adherence, but most importantly ensured that the trial was conducted to the highest ethical standards in consultation with the community.</gtr:impact><gtr:outcomeId>PJA6UCRyioR</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Entry in the EDCTP Annual Report 2013 (published June 2014)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>44403D50-B5FE-433A-9C62-E6CB94627543</gtr:id><gtr:impact>The MDP301 project which EDCTP co-funded was chosen as an example of good practice. EDCTP funding allowed microbicides to be introduced into Mozambique for the first time, with training of clinicians and researchers largely undertaken by the team from the University of Witswatersrand in Johannesburg.</gtr:impact><gtr:outcomeId>5464a1e9db3395.86076221</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://www.edctp.org/annualreport2013</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>House of Lords Select Committee chaired by Lord Fowler</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>25C77C3C-2A70-4B64-BF6F-FBBBFB9E1CCA</gtr:id><gtr:impact>Following this consultation home testing for HIV was became legal (April 2014)</gtr:impact><gtr:outcomeId>AERENfstqK2</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Consultation on Standards of Care in HIV prevention trials</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>58A84025-3AC5-4F3E-9785-C52FF2789A21</gtr:id><gtr:impact>Followed on from review of standards of care and prevention which MDP participated in.
Presentation available to other practitioners.
Report of meeting.</gtr:impact><gtr:outcomeId>VM2FZ7JYFSd</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Quick Working Group to coordinate Phase III microbicide trials</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:id>B24BF055-2171-4647-9EAA-7D1824887BC4</gtr:id><gtr:impact>Co-Chair of this international group of research organisations coordinating Phase III microbicide trials, sharing best practice.</gtr:impact><gtr:outcomeId>RsqAvfNkFgA</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>FHI 360 Gender Analysis in Microbicides</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:id>300E6369-4BB7-41E3-8D35-FDB5AB50E970</gtr:id><gtr:outcomeId>V18DjN63EBq</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>CMO Seminar on future public health policy for HIV research</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3295C94C-FA49-4A16-B01B-3D461A6F2D33</gtr:id><gtr:impact>As a result of the seminar the CMO wrote to all GPs advising them to test patients presenting with glandular fever symptoms for HIV. The legalisation of self-testing was also raised and subsequently the CMO announced that the law would be changed from April 2014.</gtr:impact><gtr:outcomeId>nm2cFyDZQkt</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Adherence data were collected by self-report, diaries and returned used applicators. During part 1 of the IDI there was a further self-report, followed by a review of the quantitative data and reconciliation to obtain the most accurate estimate of adherence to a coitally dependent vaginal gel.</gtr:description><gtr:id>7E1C9671-62C0-48A9-B51D-C10AB1599683</gtr:id><gtr:impact>This method was recommended by the Institute of Medicine Review of HIV prevention trials 2008, and subsequently adopted by several research groups. It is frequently referenced as the gold standard in the absence of a biomarker for adherence.</gtr:impact><gtr:outcomeId>iMrZwKjtP4o</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Triangulation of adherence data and reconciliation</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>MDP301 databases set up in 6 research centres in sub-Saharan Africa as well as the combined database held at MRC CTU. The data could be extracted into Access and easily manipulated by the local investigators.</gtr:description><gtr:id>34548D5A-3DA0-42CF-B5E8-9411E693A47E</gtr:id><gtr:impact>Over 60 conference abstracts submitted by African investigators who were able to extract and analyse their own data, most of which led to scholarships and some of which won awards such as best conference poster.</gtr:impact><gtr:outcomeId>DySN1ZsCVNW</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>MDP301 database</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>C3BB42D7-D94B-4DE4-B0ED-DFCB804BCAFD</gtr:id><gtr:title>Family planning methods among women in a vaginal microbicide feasibility study in rural KwaZulu-Natal, South Africa.</gtr:title><gtr:parentPublicationTitle>African journal of reproductive health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/933ed97a3947b15a32409f83822b1ac4"><gtr:id>933ed97a3947b15a32409f83822b1ac4</gtr:id><gtr:otherNames>Subramanian L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1118-4841</gtr:issn><gtr:outcomeId>N5ddhE5xZ1c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>569E0375-22E9-438F-811A-BF93173D00C5</gtr:id><gtr:title>oral presentation: Why Context Matters in Understanding the Challenges to Clinical Trials (Symposium 10, Challenges of Biomedical HIV Prevention Trials)</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8abf5759c8e695e54167ce931c1417be"><gtr:id>8abf5759c8e695e54167ce931c1417be</gtr:id><gtr:otherNames>Stadler J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545bb3c8e86e28.16520114</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0E06A0F6-2224-4F17-9B40-3927CB610903</gtr:id><gtr:title>Uptake of hormonal contraceptives and correlates of uptake in a phase III clinical trial in rural South Western Uganda.</gtr:title><gtr:parentPublicationTitle>Reproductive health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3cf5c8e0ec541774232c6d8f0012bdce"><gtr:id>3cf5c8e0ec541774232c6d8f0012bdce</gtr:id><gtr:otherNames>Abaasa A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1742-4755</gtr:issn><gtr:outcomeId>58c668694c1729.72321987</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D76E0E2-E84C-461F-83A2-562129B6999D</gtr:id><gtr:title>Genital Tract Immunological Markers in Sub-Saharan African Women with Relevance to HIV Risk and Prevention</gtr:title><gtr:parentPublicationTitle>AIDS Research and Human Retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e6af6898898d5974a6f92bb656f8b213"><gtr:id>e6af6898898d5974a6f92bb656f8b213</gtr:id><gtr:otherNames>Kyongo J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545cd22501e236.01391439</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23640E8C-DCC1-4AF1-8807-9289BF368FBD</gtr:id><gtr:title>oral presentation: Exploring Post-coital Intravaginal Cleansing Practices among Women Enrolled in the Microbicides Development Programme MDP 301 Clinical Trial (oral abstract session 02: Microbicides: Male Partner Engagement and Sexual Behaviors)</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89fbf267478571b0dfd2e4f3e548a6ba"><gtr:id>89fbf267478571b0dfd2e4f3e548a6ba</gtr:id><gtr:otherNames>Gafos M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545b8facd8f306.86222421</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BE8B593-0AFD-47F3-9BBD-BB5945CF5BE7</gtr:id><gtr:title>Prevalence of sexually transmitted infections and bacterial vaginosis among women in sub-Saharan Africa: An individual participant data meta-analysis of 18 HIV prevention studies.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a24619e8e97fd168eadaf7330b096d1"><gtr:id>7a24619e8e97fd168eadaf7330b096d1</gtr:id><gtr:otherNames>Torrone EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>5a9fbb5e696f06.54891249</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>862A9E38-B177-4AE1-9550-7819894BCB16</gtr:id><gtr:title>Critically engaging: integrating the social and the biomedical in international microbicides research.</gtr:title><gtr:parentPublicationTitle>Journal of the International AIDS Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/394b72a586ff4088949765d860a0fe1b"><gtr:id>394b72a586ff4088949765d860a0fe1b</gtr:id><gtr:otherNames>Montgomery CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1758-2652</gtr:issn><gtr:outcomeId>pm_14129_29_21968091</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F3313C3-F1AC-4E60-99FC-C916AFA4922E</gtr:id><gtr:title>Microbicides Development Programme: design of a phase III trial to measure the efficacy of the vaginal microbicide PRO 2000/5 for HIV prevention.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8f618fdecf7990e35858764386f35ae"><gtr:id>e8f618fdecf7990e35858764386f35ae</gtr:id><gtr:otherNames>Nunn A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>Dh4aMissmsS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8413ACF3-EAAE-4594-B65C-22DB991FDC99</gtr:id><gtr:title>PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba7304cedf2514ac5d61b9eba0e13eb7"><gtr:id>ba7304cedf2514ac5d61b9eba0e13eb7</gtr:id><gtr:otherNames>McCormack S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>ePuQFjayu2W</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>759BE8E6-6375-4D7D-8211-2DE715025903</gtr:id><gtr:title>The importance of context: model projections on how microbicide impact could be affected by the underlying epidemiologic and behavioral situation in 2 African settings.</gtr:title><gtr:parentPublicationTitle>Sexually transmitted diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e23fa31165fb45166da484485b37293"><gtr:id>6e23fa31165fb45166da484485b37293</gtr:id><gtr:otherNames>Vickerman P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0148-5717</gtr:issn><gtr:outcomeId>f1QRAmWS12R</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12A62AB0-A5F9-4529-921C-D159AD733221</gtr:id><gtr:title>Managing men: women's dilemmas about overt and covert use of barrier methods for HIV prevention.</gtr:title><gtr:parentPublicationTitle>Culture, health &amp; sexuality</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/82ba02cec22c7a596898b1e8cb1c28a3"><gtr:id>82ba02cec22c7a596898b1e8cb1c28a3</gtr:id><gtr:otherNames>MacPhail C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1369-1058</gtr:issn><gtr:outcomeId>ho23uuGJvTy</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AED08421-A927-4421-8E6B-BE31D756279E</gtr:id><gtr:title>Community attitudes towards individuals living with HIV in rural KwaZulu-Natal, South Africa.</gtr:title><gtr:parentPublicationTitle>AIDS care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3c81eb8eaf4503396cf1f02a73fd7f4e"><gtr:id>3c81eb8eaf4503396cf1f02a73fd7f4e</gtr:id><gtr:otherNames>Ndinda C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0954-0121</gtr:issn><gtr:outcomeId>PWySzsU69Ei</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C7D84C93-F911-43E4-9816-3C27FDD5AE6E</gtr:id><gtr:title>The implementation and appraisal of a novel confirmatory HIV-1 testing algorithm in the Microbicides Development Programme 301 Trial (MDP301).</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d808692d178396cdfab04e1a9daafa5"><gtr:id>1d808692d178396cdfab04e1a9daafa5</gtr:id><gtr:otherNames>Jentsch U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_14129_29_22984401</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A37B2B27-74FB-47E8-AFF7-959D553AD2F6</gtr:id><gtr:title>Gender relations in the context of HIV/AIDS in rural South Africa.</gtr:title><gtr:parentPublicationTitle>AIDS care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3c81eb8eaf4503396cf1f02a73fd7f4e"><gtr:id>3c81eb8eaf4503396cf1f02a73fd7f4e</gtr:id><gtr:otherNames>Ndinda C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0954-0121</gtr:issn><gtr:outcomeId>NabebCKNN6L</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0D3CBE7-2B92-4454-8770-DC64A293B914</gtr:id><gtr:title>The role of community acceptance over time for costs of HIV and STI prevention interventions: analysis of the Masaka Intervention Trial, Uganda, 1996-1999.</gtr:title><gtr:parentPublicationTitle>Sexually transmitted diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/364ab0bf33d0f2d36b2c959760be9d42"><gtr:id>364ab0bf33d0f2d36b2c959760be9d42</gtr:id><gtr:otherNames>Terris-Prestholt F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0148-5717</gtr:issn><gtr:outcomeId>dktc6hWXfLn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34262A96-D16D-439B-9D75-A3E9CF93A7D2</gtr:id><gtr:title>Long-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west Uganda.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3cf5c8e0ec541774232c6d8f0012bdce"><gtr:id>3cf5c8e0ec541774232c6d8f0012bdce</gtr:id><gtr:otherNames>Abaasa A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>pm_14129_29_23374729</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6253C9A8-58BE-4550-A95A-68F9E53C8388</gtr:id><gtr:title>'I heard about this study on the radio': using community radio to strengthen Good Participatory Practice in HIV prevention trials.</gtr:title><gtr:parentPublicationTitle>BMC public health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5599b4ef58706984af5f9813297a7701"><gtr:id>5599b4ef58706984af5f9813297a7701</gtr:id><gtr:otherNames>Medeossi BJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-2458</gtr:issn><gtr:outcomeId>545cdbd0cb8464.94826671</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E765DCA-29FC-48A3-9099-DACD09EE6817</gtr:id><gtr:title>Quality control and performance of HIV rapid tests in a microbicide clinical trial in rural KwaZulu-Natal.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42981bb5a58bd0ff5057f965fbf55e56"><gtr:id>42981bb5a58bd0ff5057f965fbf55e56</gtr:id><gtr:otherNames>von Knorring N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_14129_29_22303452</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5094A31D-98F8-4EC3-810E-C61F2901AC73</gtr:id><gtr:title>Are women who work in bars, guesthouses and similar facilities a suitable study population for vaginal microbicide trials in Africa?</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95d37d831f7cc7077db21645b8ed08ed"><gtr:id>95d37d831f7cc7077db21645b8ed08ed</gtr:id><gtr:otherNames>Vallely A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>SDx5z4PxNYE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E815922E-97E0-480E-A36D-E79B642B177B</gtr:id><gtr:title>Blockage and flow: intimate experiences of condoms and microbicides in a South African clinical trial.</gtr:title><gtr:parentPublicationTitle>Culture, health &amp; sexuality</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8abf5759c8e695e54167ce931c1417be"><gtr:id>8abf5759c8e695e54167ce931c1417be</gtr:id><gtr:otherNames>Stadler J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1369-1058</gtr:issn><gtr:outcomeId>Lx15YDcnyEw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9428684F-176B-459D-B666-482D35CD8370</gtr:id><gtr:title>Comparison of sexual behavior data collected using a coital diary and a clinic-based interview during a microbicide pilot study in Mwanza, Tanzania.</gtr:title><gtr:parentPublicationTitle>Sexually transmitted diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab512941caeb1aae2accf5cc6383f6ac"><gtr:id>ab512941caeb1aae2accf5cc6383f6ac</gtr:id><gtr:otherNames>Lees S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0148-5717</gtr:issn><gtr:outcomeId>rdF3qMLf3K1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DF54890-6C5B-4619-82E3-5D72D5D7EA29</gtr:id><gtr:title>A mixed methods and triangulation model for increasing the accuracy of adherence and sexual behaviour data: the Microbicides Development Programme.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f40f767256bf24f772526e320bc61de"><gtr:id>0f40f767256bf24f772526e320bc61de</gtr:id><gtr:otherNames>Pool R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>TgX1HWbA9v6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15ECBED9-3210-4353-BA38-E6BF62D04D36</gtr:id><gtr:title>Direct measurement of in-vivo vaginal microbicide levels of PRO 2000 achieved in a human safety study.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/361d8ef50375d4b3bff5b57b03e3d959"><gtr:id>361d8ef50375d4b3bff5b57b03e3d959</gtr:id><gtr:otherNames>Lacey CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>NZMFESbAETF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED97F78F-3DB9-44F2-B428-E5F7A8CA2C2D</gtr:id><gtr:title>Candidate polyanion microbicides inhibit HIV-1 infection and dissemination pathways in human cervical explants.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94cb3fe7de1f077310ae111f2c508edf"><gtr:id>94cb3fe7de1f077310ae111f2c508edf</gtr:id><gtr:otherNames>Fletcher PS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>NuHmTVtZDBq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E3F17C1-8999-45BB-B7CB-D1D7142A07F1</gtr:id><gtr:title>Off Label</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df1d40a7862b3f516ba01d3f96bedee3"><gtr:id>df1d40a7862b3f516ba01d3f96bedee3</gtr:id><gtr:otherNames>Stadler, Jonathan</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:isbn>978-1-86854-728-9</gtr:isbn><gtr:outcomeId>SYGFRQ2jL5U</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CAC265A2-92D7-4ACA-8ECD-5CD3EF12AFAA</gtr:id><gtr:title>Geographical clustering of high risk sexual behaviors in &amp;quot;hot-spots&amp;quot; for HIV and sexually transmitted infections in Kwazulu-Natal, South Africa.</gtr:title><gtr:parentPublicationTitle>AIDS and behavior</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2fb619ef0baba886f95886c59fc5ddf"><gtr:id>f2fb619ef0baba886f95886c59fc5ddf</gtr:id><gtr:otherNames>Ramjee G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1090-7165</gtr:issn><gtr:outcomeId>544e6975be79e6.98530378</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CFDEEDAA-E1E6-466A-B231-66C17E2BF073</gtr:id><gtr:title>Validity of coital diaries in a feasibility study for the Microbicides Development Programme trial among women at high risk of HIV/AIDS in Mwanza, Tanzania.</gtr:title><gtr:parentPublicationTitle>Sexually transmitted infections</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c101700f19571c90b93dcd262ed68e1a"><gtr:id>c101700f19571c90b93dcd262ed68e1a</gtr:id><gtr:otherNames>Allen CF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1368-4973</gtr:issn><gtr:outcomeId>jzC1na2cA6s</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7256B21-C6AF-43A5-872F-DED39F26B902</gtr:id><gtr:title>The challenge of defining standards of prevention in HIV prevention trials.</gtr:title><gtr:parentPublicationTitle>Journal of medical ethics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/860d34ad7a9af5b0d4cc8ad1aff097d7"><gtr:id>860d34ad7a9af5b0d4cc8ad1aff097d7</gtr:id><gtr:otherNames>Philpott S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0306-6800</gtr:issn><gtr:outcomeId>pm_14129_29_21186207</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E1B47AE9-0CEC-416F-9E94-ABC65A6CB2F7</gtr:id><gtr:title>Ethical considerations in determining standard of prevention packages for HIV prevention trials: examining PrEP.</gtr:title><gtr:parentPublicationTitle>Developing world bioethics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d1bb197cc904bb6e54a57f5b78db9ae"><gtr:id>2d1bb197cc904bb6e54a57f5b78db9ae</gtr:id><gtr:otherNames>Haire B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-8731</gtr:issn><gtr:outcomeId>pm_14129_29_23725227</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8FE9FA3B-178B-4AFD-BBA3-DFB3B319928B</gtr:id><gtr:title>Assessing the accuracy of adherence and sexual behaviour data in the MDP301 vaginal microbicides trial using a mixed methods and triangulation model.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f40f767256bf24f772526e320bc61de"><gtr:id>0f40f767256bf24f772526e320bc61de</gtr:id><gtr:otherNames>Pool R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>aMKemGgzrZ8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A409487F-B6BB-451C-94BF-4AFC1E2AF016</gtr:id><gtr:title>Experiences in conducting multiple community-based HIV prevention trials among women in KwaZulu-Natal, South Africa.</gtr:title><gtr:parentPublicationTitle>AIDS research and therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2fb619ef0baba886f95886c59fc5ddf"><gtr:id>f2fb619ef0baba886f95886c59fc5ddf</gtr:id><gtr:otherNames>Ramjee G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1742-6405</gtr:issn><gtr:outcomeId>doi_55f983983681f4fa</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50103779-3A69-4DE5-A024-A9A6AFC857BA</gtr:id><gtr:title>Re: &amp;quot;Enhancement of HIV infection by cellulose sulfate,&amp;quot; by Tao et al.</gtr:title><gtr:parentPublicationTitle>AIDS research and human retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba7304cedf2514ac5d61b9eba0e13eb7"><gtr:id>ba7304cedf2514ac5d61b9eba0e13eb7</gtr:id><gtr:otherNames>McCormack S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0889-2229</gtr:issn><gtr:outcomeId>ihGdNc47UB3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A46263A0-BACE-4419-9269-37208B36C2E4</gtr:id><gtr:title>Ethics, justice and community participation in the Microbicides Development Programme (MDP) Phase III trial in Mwanza, Tanzania.</gtr:title><gtr:parentPublicationTitle>The American journal of bioethics : AJOB</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95d37d831f7cc7077db21645b8ed08ed"><gtr:id>95d37d831f7cc7077db21645b8ed08ed</gtr:id><gtr:otherNames>Vallely A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1526-5161</gtr:issn><gtr:outcomeId>pm_14129_29_23072681</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DEBB3CB5-1BBD-4886-A3E9-175480ECBAD8</gtr:id><gtr:title>High prevalence and incidence of sexually transmitted infections among women living in Kwazulu-Natal, South Africa.</gtr:title><gtr:parentPublicationTitle>AIDS research and therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c466ae98f118459939cc3dd07cd9570d"><gtr:id>c466ae98f118459939cc3dd07cd9570d</gtr:id><gtr:otherNames>Naidoo S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1742-6405</gtr:issn><gtr:outcomeId>doi_55faa1aa16c947a0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60E0F3FD-A77F-47E4-8DA8-7F7FC349B9AB</gtr:id><gtr:title>Pregnancy in HIV clinical trials in Sub Saharan Africa: failure of consent or contraception?</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/440d093fa0202c6122edc3ba737de762"><gtr:id>440d093fa0202c6122edc3ba737de762</gtr:id><gtr:otherNames>Ssali A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>546256ac66e9e9.13074195</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB0A7267-8860-498C-B883-A8523CEA35BE</gtr:id><gtr:title>'The study has taught me to be supportive of her': empowering women and involving men in microbicide research.</gtr:title><gtr:parentPublicationTitle>Culture, health &amp; sexuality</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04d4908d6a03e3064f431abb1a806b34"><gtr:id>04d4908d6a03e3064f431abb1a806b34</gtr:id><gtr:otherNames>Venables E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1369-1058</gtr:issn><gtr:outcomeId>GedHQ7yvdnf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7338F55-2A68-479F-8867-CF8EA10DAE14</gtr:id><gtr:title>Microbicides development programme: engaging the community in the standard of care debate in a vaginal microbicide trial in Mwanza, Tanzania.</gtr:title><gtr:parentPublicationTitle>BMC medical ethics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95d37d831f7cc7077db21645b8ed08ed"><gtr:id>95d37d831f7cc7077db21645b8ed08ed</gtr:id><gtr:otherNames>Vallely A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1472-6939</gtr:issn><gtr:outcomeId>LTAkVHUWyxG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>115C48E9-A371-4BE2-8ABA-A2843BC6CD7E</gtr:id><gtr:title>HIV incidence among non-pregnant women living in selected rural, semi-rural and urban areas in KwaZulu-Natal, South Africa.</gtr:title><gtr:parentPublicationTitle>AIDS and behavior</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2fb619ef0baba886f95886c59fc5ddf"><gtr:id>f2fb619ef0baba886f95886c59fc5ddf</gtr:id><gtr:otherNames>Ramjee G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1090-7165</gtr:issn><gtr:outcomeId>K4yfg5SimBQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1734F0F0-7BA3-4602-9882-49EF6732F8BF</gtr:id><gtr:title>Intravaginal insertion in KwaZulu-Natal: sexual practices and preferences in the context of microbicide gel use.</gtr:title><gtr:parentPublicationTitle>Culture, health &amp; sexuality</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89fbf267478571b0dfd2e4f3e548a6ba"><gtr:id>89fbf267478571b0dfd2e4f3e548a6ba</gtr:id><gtr:otherNames>Gafos M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1369-1058</gtr:issn><gtr:outcomeId>jFPXFYoEWCf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96CE0E48-82ED-4DFD-BCEF-B92C79C9B558</gtr:id><gtr:title>A tale of two &amp;quot;cultures&amp;quot;: HIV risk narratives in South Africa.</gtr:title><gtr:parentPublicationTitle>Medical anthropology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bee8f0af3d4cee71c681591ff39fa4e4"><gtr:id>bee8f0af3d4cee71c681591ff39fa4e4</gtr:id><gtr:otherNames>Saethre E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0145-9740</gtr:issn><gtr:outcomeId>eHs1VuxNWyZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D05261C-4C9D-4ACF-955A-5AF519F4A445</gtr:id><gtr:title>Re-framing microbicide acceptability: findings from the MDP301 trial.</gtr:title><gtr:parentPublicationTitle>Culture, health &amp; sexuality</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/394b72a586ff4088949765d860a0fe1b"><gtr:id>394b72a586ff4088949765d860a0fe1b</gtr:id><gtr:otherNames>Montgomery CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1369-1058</gtr:issn><gtr:outcomeId>n9XzmxAPRVM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DAA459C-3C6A-4ACF-907A-D25382A7D1EA</gtr:id><gtr:title>HIV and dyadic intervention: an interdependence and communal coping analysis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/394b72a586ff4088949765d860a0fe1b"><gtr:id>394b72a586ff4088949765d860a0fe1b</gtr:id><gtr:otherNames>Montgomery CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_14129_29_22808227</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF93EE74-30E9-41DC-9538-E6BA2C4658CD</gtr:id><gtr:title>Shared responsibility for ensuring appropriate management of incidental findings: a case study from South Africa.</gtr:title><gtr:parentPublicationTitle>Journal of medical ethics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3bd7edcd755cc6bc526fc8c795402462"><gtr:id>3bd7edcd755cc6bc526fc8c795402462</gtr:id><gtr:otherNames>Sookrajh Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0306-6800</gtr:issn><gtr:outcomeId>546254330df591.57583368</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39AD3D57-212A-4B2F-AAAC-F26D7666267D</gtr:id><gtr:title>Perceptions of anal sex in rural South Africa.</gtr:title><gtr:parentPublicationTitle>Culture, health &amp; sexuality</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3c81eb8eaf4503396cf1f02a73fd7f4e"><gtr:id>3c81eb8eaf4503396cf1f02a73fd7f4e</gtr:id><gtr:otherNames>Ndinda C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1369-1058</gtr:issn><gtr:outcomeId>B2QG7uQRzo3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E7539C4-8E99-42C7-81FD-5D4EE0CD2B27</gtr:id><gtr:title>poster: Antiretroviral (ARV)-Based Prevention for Women: A Review of Factors Influencing Choice, Adherence and Potential Success of Product Formulations</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1fcc134cff7ca4048dad76a7ecaf0597"><gtr:id>1fcc134cff7ca4048dad76a7ecaf0597</gtr:id><gtr:otherNames>Tolley E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545b5d037eac06.65759777</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6E2A219-3B34-4F3C-8DC3-D19BB6D3B7ED</gtr:id><gtr:title>Combined impact of sexual risk behaviors for HIV seroconversion among women in Durban, South Africa: implications for prevention policy and planning.</gtr:title><gtr:parentPublicationTitle>AIDS and behavior</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69ee4e6d872e105b9c2c2dbaf4eaa52b"><gtr:id>69ee4e6d872e105b9c2c2dbaf4eaa52b</gtr:id><gtr:otherNames>Wand H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1090-7165</gtr:issn><gtr:outcomeId>pm_14129_29_20981479</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8913B94-F1CB-44FE-8647-BD35B8CB1826</gtr:id><gtr:title>From trial intervention to scale-up: costs of an adolescent sexual health program in Mwanza, Tanzania.</gtr:title><gtr:parentPublicationTitle>Sexually transmitted diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/364ab0bf33d0f2d36b2c959760be9d42"><gtr:id>364ab0bf33d0f2d36b2c959760be9d42</gtr:id><gtr:otherNames>Terris-Prestholt F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0148-5717</gtr:issn><gtr:outcomeId>fYknhmf2inZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D30DC87-4A8E-4A56-B040-A2FB6961EEEB</gtr:id><gtr:title>Which topical microbicides for blocking HIV-1 transmission will work in the real world?</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a6211d70604c09a697661a128171fa98"><gtr:id>a6211d70604c09a697661a128171fa98</gtr:id><gtr:otherNames>Klasse PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>g9FgZfptsMF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37761E17-7AE0-4164-8C45-8CFDB32CEFAE</gtr:id><gtr:title>Microbicides development program, Tanzania-baseline characteristics of an occupational cohort and reattendance at 3 months.</gtr:title><gtr:parentPublicationTitle>Sexually transmitted diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95d37d831f7cc7077db21645b8ed08ed"><gtr:id>95d37d831f7cc7077db21645b8ed08ed</gtr:id><gtr:otherNames>Vallely A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0148-5717</gtr:issn><gtr:outcomeId>U9M8SzRNARC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47AE1CBB-CC52-46E6-9C60-234649A65AF3</gtr:id><gtr:title>Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e592a67027098903f7c40312ef17e6de"><gtr:id>e592a67027098903f7c40312ef17e6de</gtr:id><gtr:otherNames>Morrison CS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>56b1d5523c57c4.62705207</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A5127D2-544C-49D8-AD6E-2B780A458194</gtr:id><gtr:title>Using modeling to explore the degree to which a microbicide's sexually transmitted infection efficacy may contribute to the HIV effectiveness measured in phase 3 microbicide trials.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e23fa31165fb45166da484485b37293"><gtr:id>6e23fa31165fb45166da484485b37293</gtr:id><gtr:otherNames>Vickerman P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>HjHgvysVoBu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42158626-86F8-41C6-8A70-1BBEB74710CB</gtr:id><gtr:title>The potential for central monitoring techniques to replace on-site monitoring: findings from an international multi-centre clinical trial.</gtr:title><gtr:parentPublicationTitle>Clinical trials (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b845507a87257cb3fbd03f2c3ea6cc40"><gtr:id>b845507a87257cb3fbd03f2c3ea6cc40</gtr:id><gtr:otherNames>Bakobaki JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1740-7745</gtr:issn><gtr:outcomeId>c36wcoi8SQB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ADEA2541-F282-420A-8114-A558819DAE58</gtr:id><gtr:title>Sexual risk behaviour for women working in recreational venues in Mwanza, Tanzania: considerations for the acceptability and use of vaginal microbicide gels.</gtr:title><gtr:parentPublicationTitle>Culture, health &amp; sexuality</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab512941caeb1aae2accf5cc6383f6ac"><gtr:id>ab512941caeb1aae2accf5cc6383f6ac</gtr:id><gtr:otherNames>Lees S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1369-1058</gtr:issn><gtr:outcomeId>NxEuhHh5cCZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8E4C416-8A24-4820-9E7C-9CD4A7FC958E</gtr:id><gtr:title>The British HIV Association/British Association for Sexual Health and HIV Position Statement on pre-exposure prophylaxis in the UK.</gtr:title><gtr:parentPublicationTitle>International journal of STD &amp; AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba7304cedf2514ac5d61b9eba0e13eb7"><gtr:id>ba7304cedf2514ac5d61b9eba0e13eb7</gtr:id><gtr:otherNames>McCormack S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0956-4624</gtr:issn><gtr:outcomeId>pm_14129_29_22362679</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A3723D9-6A13-4C40-9D42-097BA81A687D</gtr:id><gtr:title>Attaining realistic and substantial reductions in HIV incidence: model projections of combining microbicide and male circumcision interventions in rural Uganda.</gtr:title><gtr:parentPublicationTitle>Sexually transmitted infections</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72d93573b3d4d7e99a88dd575e608349"><gtr:id>72d93573b3d4d7e99a88dd575e608349</gtr:id><gtr:otherNames>Cox AP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1368-4973</gtr:issn><gtr:outcomeId>M5SKZBvqRZr</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC7B26B0-BD6A-42D7-A6BC-2B9C2B60CE21</gtr:id><gtr:title>The role of progestins in HIV acquisition in young women.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2fb619ef0baba886f95886c59fc5ddf"><gtr:id>f2fb619ef0baba886f95886c59fc5ddf</gtr:id><gtr:otherNames>Ramjee G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>56b1d5516ffdc2.72205117</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C45972A-C25C-43A7-9D67-5C9A07D9E85E</gtr:id><gtr:title>Making prevention public: The co-production of gender and technology in HIV prevention research</gtr:title><gtr:parentPublicationTitle>Social Studies of Science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/738e0a0b0f2ac83c08733141c5c047b0"><gtr:id>738e0a0b0f2ac83c08733141c5c047b0</gtr:id><gtr:otherNames>Montgomery C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>g1E8bLtyHJ5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB08E6A0-7B5D-4B73-A516-967D275D275B</gtr:id><gtr:title>Malicious whites, greedy women, and virtuous volunteers: negotiating social relations through clinical trial narratives in South Africa.</gtr:title><gtr:parentPublicationTitle>Medical anthropology quarterly</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bee8f0af3d4cee71c681591ff39fa4e4"><gtr:id>bee8f0af3d4cee71c681591ff39fa4e4</gtr:id><gtr:otherNames>Saethre E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0745-5194</gtr:issn><gtr:outcomeId>pm_14129_29_23674325</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CAB5034-7370-4C58-97B1-3D0808B80832</gtr:id><gtr:title>oral presentation: What Do We Really Mean By &amp;quot;Adherence&amp;quot; in Vaginal Microbicide Trials? A Comparative Study</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4eb4a7e2cf5babdd4f5aeed8e9849645"><gtr:id>4eb4a7e2cf5babdd4f5aeed8e9849645</gtr:id><gtr:otherNames>Miller L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545aba7ba8df02.72508686</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99943370-A123-428F-85FE-050E7A7CA7A0</gtr:id><gtr:title>Population-level impact of hormonal contraception on incidence of HIV infection and pregnancy in women in Durban, South Africa.</gtr:title><gtr:parentPublicationTitle>Bulletin of the World Health Organization</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2fb619ef0baba886f95886c59fc5ddf"><gtr:id>f2fb619ef0baba886f95886c59fc5ddf</gtr:id><gtr:otherNames>Ramjee G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0042-9686</gtr:issn><gtr:outcomeId>pDPBZ2n9HBQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8042E03-0124-48E3-B45F-80B6CCBE8FC3</gtr:id><gtr:title>Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94cb3fe7de1f077310ae111f2c508edf"><gtr:id>94cb3fe7de1f077310ae111f2c508edf</gtr:id><gtr:otherNames>Fletcher PS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>GyJ2UgMY7jm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>822644BB-4754-4767-AB62-C7C7B3571A8E</gtr:id><gtr:title>EDCTP Annual Report 2013</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd4b7d4599d04593792ac2562d0cc227"><gtr:id>fd4b7d4599d04593792ac2562d0cc227</gtr:id><gtr:otherNames>EDCTP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:isbn>-</gtr:isbn><gtr:outcomeId>545bb8d42a7988.91262683</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>992FAEE9-5508-4C25-9693-69978EBC6D49</gtr:id><gtr:title>Prevalence of Herpes Simplex Virus 2 (HSV-2) infection and associated risk factors in a cohort of HIV negative women in Durban, South Africa.</gtr:title><gtr:parentPublicationTitle>BMC research notes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/574366aefb678b01920bb269e942f55b"><gtr:id>574366aefb678b01920bb269e942f55b</gtr:id><gtr:otherNames>Daniels B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1756-0500</gtr:issn><gtr:outcomeId>5a2fd569515031.33031891</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9C86D9E-4860-4C5A-B39E-20511B030F31</gtr:id><gtr:title>How effective is effective enough? Opinions of potential end-users of microbicides from a rural South African community.</gtr:title><gtr:parentPublicationTitle>AIDS care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89fbf267478571b0dfd2e4f3e548a6ba"><gtr:id>89fbf267478571b0dfd2e4f3e548a6ba</gtr:id><gtr:otherNames>Gafos M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0954-0121</gtr:issn><gtr:outcomeId>pm_14129_29_22971053</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B07F156-1BEB-48F5-B31C-911CFE40FB97</gtr:id><gtr:title>Sexual coercion and sexual desire: ambivalent meanings of heterosexual anal sex in Soweto, South Africa.</gtr:title><gtr:parentPublicationTitle>AIDS care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9dff6ae0e1397eee6777606ad8d7f39"><gtr:id>e9dff6ae0e1397eee6777606ad8d7f39</gtr:id><gtr:otherNames>Stadler JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0954-0121</gtr:issn><gtr:outcomeId>RX4CUEgPqXv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7416B7F3-5E4C-4732-862D-96783DB24BA0</gtr:id><gtr:title>Are targeted HIV prevention activities cost-effective in high prevalence settings? Results from a sexually transmitted infection treatment project for sex workers in Johannesburg, South Africa.</gtr:title><gtr:parentPublicationTitle>Sexually transmitted diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e23fa31165fb45166da484485b37293"><gtr:id>6e23fa31165fb45166da484485b37293</gtr:id><gtr:otherNames>Vickerman P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0148-5717</gtr:issn><gtr:outcomeId>oJgywBQucKR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA902B7B-1C14-435B-ADEE-9D0859FC562A</gtr:id><gtr:title>Hidden harms: women's narratives of intimate partner violence in a microbicide trial, South Africa.</gtr:title><gtr:parentPublicationTitle>Social science &amp; medicine (1982)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8abf5759c8e695e54167ce931c1417be"><gtr:id>8abf5759c8e695e54167ce931c1417be</gtr:id><gtr:otherNames>Stadler J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0277-9536</gtr:issn><gtr:outcomeId>545cdfccc55fb0.72564065</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>927CFA65-6BD5-4545-8934-5ABCF9296C4B</gtr:id><gtr:title>Microbicide clinical trial adherence: insights for introduction.</gtr:title><gtr:parentPublicationTitle>Journal of the International AIDS Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e32eed516dff4b5430c99619f7cdddf7"><gtr:id>e32eed516dff4b5430c99619f7cdddf7</gtr:id><gtr:otherNames>Woodsong C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1758-2652</gtr:issn><gtr:outcomeId>pm_14129_29_23561044</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21A7A17C-6470-42BA-9F8C-7D19602BA91B</gtr:id><gtr:title>Oral presentation: 'Hidden Heterogeneity: Uncovering Patterns of Adherence in Microbicide Trials' (Oral abstract session 15: PrEP and Microbicide Adherence in Women)</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4eb4a7e2cf5babdd4f5aeed8e9849645"><gtr:id>4eb4a7e2cf5babdd4f5aeed8e9849645</gtr:id><gtr:otherNames>Miller L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545b8db30927c0.27072507</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16226E0E-D61F-403E-A288-41830B5ED31E</gtr:id><gtr:title>Unacceptable side-effects associated with a hyperosmolar vaginal microbicide in a phase 1 trial.</gtr:title><gtr:parentPublicationTitle>International journal of STD &amp; AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/361d8ef50375d4b3bff5b57b03e3d959"><gtr:id>361d8ef50375d4b3bff5b57b03e3d959</gtr:id><gtr:otherNames>Lacey CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0956-4624</gtr:issn><gtr:outcomeId>S2rYJvJ492f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD896F24-4423-4C91-AFAF-FB6777735DCA</gtr:id><gtr:title>High HIV prevalence and incidence among women in Southern Mozambique: Evidence from the MDP microbicide feasibility study.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/620f7475a9dabd965ead382d723bbe0e"><gtr:id>620f7475a9dabd965ead382d723bbe0e</gtr:id><gtr:otherNames>Mocumbi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5a8bdd054f0ed6.90000089</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B5248DF-1857-43FF-879F-C950590E5D37</gtr:id><gtr:title>Drug Delivery and Development of Anti-HIV Microbicides</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1fcc134cff7ca4048dad76a7ecaf0597"><gtr:id>1fcc134cff7ca4048dad76a7ecaf0597</gtr:id><gtr:otherNames>Tolley E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56d852c340a835.47771294</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B02FBD0-5208-483E-98E7-2FC92A0DB713</gtr:id><gtr:title>Protocols and participatory democracy in a 'North-South' product development partnership.</gtr:title><gtr:parentPublicationTitle>Sociology of health &amp; illness</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/394b72a586ff4088949765d860a0fe1b"><gtr:id>394b72a586ff4088949765d860a0fe1b</gtr:id><gtr:otherNames>Montgomery CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0141-9889</gtr:issn><gtr:outcomeId>pm_14129_29_22384948</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8E431F7-9D5E-4B41-B4B1-32260CC8F27B</gtr:id><gtr:title>The effects of injectable hormonal contraceptives on HIV seroconversion and on sexually transmitted infections.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69ee4e6d872e105b9c2c2dbaf4eaa52b"><gtr:id>69ee4e6d872e105b9c2c2dbaf4eaa52b</gtr:id><gtr:otherNames>Wand H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_14129_29_22156970</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97CFE51F-AD1E-41D7-9059-143852247D4A</gtr:id><gtr:title>The benefits of participatory methodologies to develop effective community dialogue in the context of a microbicide trial feasibility study in Mwanza, Tanzania.</gtr:title><gtr:parentPublicationTitle>BMC public health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95d37d831f7cc7077db21645b8ed08ed"><gtr:id>95d37d831f7cc7077db21645b8ed08ed</gtr:id><gtr:otherNames>Vallely A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1471-2458</gtr:issn><gtr:outcomeId>s1DGTpLMSUn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E59EA82-7646-48FA-98C7-A9509AFBBAAD</gtr:id><gtr:title>Women's perceptions and experiences of HIV prevention trials in Soweto, South Africa.</gtr:title><gtr:parentPublicationTitle>Social science &amp; medicine (1982)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9dff6ae0e1397eee6777606ad8d7f39"><gtr:id>e9dff6ae0e1397eee6777606ad8d7f39</gtr:id><gtr:otherNames>Stadler JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0277-9536</gtr:issn><gtr:outcomeId>qoumubrZimz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA47CF0E-9CDC-4BE6-86FD-C2D6A6B80F7A</gtr:id><gtr:title>Multipurpose prevention technologies for reproductive health: advancing the scientific and product development agenda</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a68c7518fc6c32f28ccb9be4bf7732b0"><gtr:id>a68c7518fc6c32f28ccb9be4bf7732b0</gtr:id><gtr:otherNames>Hemmerling A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>sEjmYiyEN4w</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61E23554-E20D-401A-B0E8-7577FFF64B1C</gtr:id><gtr:title>Emergent HIV technology: urban Tanzanian women's narratives of medical research, microbicides and sexuality.</gtr:title><gtr:parentPublicationTitle>Culture, health &amp; sexuality</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab512941caeb1aae2accf5cc6383f6ac"><gtr:id>ab512941caeb1aae2accf5cc6383f6ac</gtr:id><gtr:otherNames>Lees S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1369-1058</gtr:issn><gtr:outcomeId>doi_55faa1aa16c0991a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63B6F06A-E0AD-4084-AC8A-D0E2E3360DDE</gtr:id><gtr:title>Suitability of simple human immunodeficiency virus rapid tests in clinical trials in community-based clinic settings.</gtr:title><gtr:parentPublicationTitle>Journal of clinical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/956b282636f8fe08438e0143dba8bf95"><gtr:id>956b282636f8fe08438e0143dba8bf95</gtr:id><gtr:otherNames>Everett DB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0095-1137</gtr:issn><gtr:outcomeId>ErSSDup4vcN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB6B9110-6962-4E49-9FB6-485B78BE3C7D</gtr:id><gtr:title>Gelling medical knowledge: innovative pharmaceuticals, experience, and perceptions of efficacy.</gtr:title><gtr:parentPublicationTitle>Anthropology &amp; medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fec40eccb2a1d73047c86ca86ae945f0"><gtr:id>fec40eccb2a1d73047c86ca86ae945f0</gtr:id><gtr:otherNames>Saethre EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1364-8470</gtr:issn><gtr:outcomeId>VKf1XbbbmhK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95A8BE98-F168-47EE-98BC-F60569B4C354</gtr:id><gtr:title>In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d32d73b65b6ec8ad988cd6a048812cf2"><gtr:id>d32d73b65b6ec8ad988cd6a048812cf2</gtr:id><gtr:otherNames>Beer BE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>WZF6KJJgnpF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7DBA9F58-97F8-4DF6-92C8-EAD914F3131D</gtr:id><gtr:title>How informed is consent in vulnerable populations? Experience using a continuous consent process during the MDP301 vaginal microbicide trial in Mwanza, Tanzania.</gtr:title><gtr:parentPublicationTitle>BMC medical ethics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95d37d831f7cc7077db21645b8ed08ed"><gtr:id>95d37d831f7cc7077db21645b8ed08ed</gtr:id><gtr:otherNames>Vallely A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1472-6939</gtr:issn><gtr:outcomeId>EupdNP4HnYo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96C4D481-775A-4CD2-B6C4-B4EA7C7A54C1</gtr:id><gtr:title>Bacterial Vaginosis and HIV: An Analysis of the MDP301 Trial</gtr:title><gtr:parentPublicationTitle>AIDS Research and Human Retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c886ea6a1f8c575a3e82ba71366caa9"><gtr:id>7c886ea6a1f8c575a3e82ba71366caa9</gtr:id><gtr:otherNames>Joseph S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545cd34e8141f8.75499253</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47EDE33C-60C6-4349-ABD1-E17C2A3F7102</gtr:id><gtr:title>The role of partnership dynamics in determining the acceptability of condoms and microbicides.</gtr:title><gtr:parentPublicationTitle>AIDS care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/394b72a586ff4088949765d860a0fe1b"><gtr:id>394b72a586ff4088949765d860a0fe1b</gtr:id><gtr:otherNames>Montgomery CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0954-0121</gtr:issn><gtr:outcomeId>N4oVWWJw8Pj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF2E0A28-DBBF-4345-9408-36ACE8E34B11</gtr:id><gtr:title>The implications of post-coital intravaginal cleansing for the introduction of vaginal microbicides in South Africa.</gtr:title><gtr:parentPublicationTitle>AIDS and behavior</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89fbf267478571b0dfd2e4f3e548a6ba"><gtr:id>89fbf267478571b0dfd2e4f3e548a6ba</gtr:id><gtr:otherNames>Gafos M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1090-7165</gtr:issn><gtr:outcomeId>544fb588340573.84380444</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04B9C797-F45C-475B-B91E-4D5FEDA002B8</gtr:id><gtr:title>HIV prevention research: taking stock and the way forward.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c148e9ffd758a895718cfd9de060388a"><gtr:id>c148e9ffd758a895718cfd9de060388a</gtr:id><gtr:otherNames>Hayes R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>PoFtx7ohm73</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B85018D6-C17B-42F6-AC77-F462D0DB054D</gtr:id><gtr:title>Communication About Microbicide Use Between Couples in KwaZulu-Natal, South Africa.</gtr:title><gtr:parentPublicationTitle>AIDS and behavior</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89fbf267478571b0dfd2e4f3e548a6ba"><gtr:id>89fbf267478571b0dfd2e4f3e548a6ba</gtr:id><gtr:otherNames>Gafos M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1090-7165</gtr:issn><gtr:outcomeId>54900c66767fb3.61564962</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2F96861-CB62-4868-9AB7-420A92C26140</gtr:id><gtr:title>A model for community representation and participation in HIV prevention trials among women who engage in transactional sex in Africa.</gtr:title><gtr:parentPublicationTitle>AIDS care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/453f8722228f286af15e9492c58eee82"><gtr:id>453f8722228f286af15e9492c58eee82</gtr:id><gtr:otherNames>Shagi C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0954-0121</gtr:issn><gtr:outcomeId>fcA69AtNGxi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52721898-E6D5-40E6-8C86-5676E1833166</gtr:id><gtr:title>Microbicides from a regulatory perspective.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a70acb9aba00435f9a0a4de5461d1ec"><gtr:id>5a70acb9aba00435f9a0a4de5461d1ec</gtr:id><gtr:otherNames>Stone AB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>54625508515065.13576160</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED00A2D3-616E-4250-B46B-BDC2918EDD1D</gtr:id><gtr:title>A randomised placebo-controlled safety and acceptability trial of PRO 2000 vaginal microbicide gel in sexually active women in Uganda.</gtr:title><gtr:parentPublicationTitle>Sexually transmitted infections</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21a3448ce66ad1b34fedc9090711c087"><gtr:id>21a3448ce66ad1b34fedc9090711c087</gtr:id><gtr:otherNames>Kamali A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1368-4973</gtr:issn><gtr:outcomeId>C3Pn7Bebv7e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31A7CEE5-9AA1-4136-A151-67FB7659D104</gtr:id><gtr:title>&amp;quot;One teabag is better than four&amp;quot;: Participants response to the discontinuation of 2% PRO2000/5 microbicide gel in KwaZulu-Natal, South Africa.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89fbf267478571b0dfd2e4f3e548a6ba"><gtr:id>89fbf267478571b0dfd2e4f3e548a6ba</gtr:id><gtr:otherNames>Gafos M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>EHDhg2CfPR2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22BBD523-1FA1-4FE7-8E3B-B1B7502DAA4D</gtr:id><gtr:title>Injectable and oral contraceptives and risk of HIV acquisition in women: an analysis of data from the MDP301 trial.</gtr:title><gtr:parentPublicationTitle>Human reproduction (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d16a0e2cac032025257ed2f44c93f19d"><gtr:id>d16a0e2cac032025257ed2f44c93f19d</gtr:id><gtr:otherNames>Crook AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0268-1161</gtr:issn><gtr:outcomeId>544fb5886b6026.12952029</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3775FD1-035C-4937-ADCF-43C99BAAD92D</gtr:id><gtr:title>Targeting the hotspots: investigating spatial and demographic variations in HIV infection in small communities in South Africa.</gtr:title><gtr:parentPublicationTitle>Journal of the International AIDS Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69ee4e6d872e105b9c2c2dbaf4eaa52b"><gtr:id>69ee4e6d872e105b9c2c2dbaf4eaa52b</gtr:id><gtr:otherNames>Wand H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1758-2652</gtr:issn><gtr:outcomeId>pm_14129_29_20979651</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24C2E820-62EB-4FAD-B8FE-2A336CC20C05</gtr:id><gtr:title>Engaging male partners in women's microbicide use: evidence from clinical trials and implications for future research and microbicide introduction.</gtr:title><gtr:parentPublicationTitle>Journal of the International AIDS Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c9a53574c8bab233260b7283f1a1653"><gtr:id>4c9a53574c8bab233260b7283f1a1653</gtr:id><gtr:otherNames>Lanham M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1758-2652</gtr:issn><gtr:outcomeId>54648917a800b4.71271446</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0100137</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>